96829-58-2 | (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
1g	98%	in stock	$13.00	$9.00
5g	97%	in stock	$50.00	$35.00
25g	97%	in stock	$163.00	$114.00
100g	97%	in stock	$511.00	$358.00

Description

• Catalog Number: AB46811
• Chemical Name: (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate
• CAS Number: 96829-58-2
• Molecular Formula: C29H53NO5
• Molecular Weight: 495.7348
• MDL Number: MFCD05662360
• SMILES: CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

Computed Properties

• Complexity: 579
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 23
• XLogP3: 10

Literature

• A pharmacologic increase in activity of plasma transaminase derived from small intestine in animals receiving an acyl CoA: diacylglycerol transferase (DGAT) 1 inhibitor.

  The Journal of toxicological sciences 20180101

• Why are most phospholipidosis inducers also hERG blockers?

  Archives of toxicology 20171201

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• Mitigating efficacy of piperine in the physiological derangements of high fat diet induced obesity in Sprague Dawley rats.

  Chemico-biological interactions 20140925

• Qualitative screening for adulterants in weight-loss supplements by ion mobility spectrometry.

  Journal of pharmaceutical and biomedical analysis 20121201

• Hypolipidemic applications of microcrystalline cellulose composite synthesized from different agricultural residues.

  International journal of biological macromolecules 20121201

• Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.

  Bioorganic & medicinal chemistry 20121115

• Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules.

  Biochimica et biophysica acta 20121101

• Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial.

  European journal of endocrinology 20121101

• Substrate-like water soluble lipase inhibitors from Filipendula kamtschatica.

  Bioorganic & medicinal chemistry letters 20121015

• Evaluation of mutagenic effect of two antiobesity drugs on mice's genetic materials.

  Drug and chemical toxicology 20121001

• Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat.

  Journal of cardiovascular pharmacology 20121001

• Recent advancements in drug treatment of obesity.

  Clinical medicine (London, England) 20121001

• Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors.

  The Journal of biological chemistry 20120907

• The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.

  British journal of cancer 20120904

• Loss of control of HIV viremia associated with the fat malabsorption drug orlistat.

  AIDS research and human retroviruses 20120901

• Lagenaria siceraria fruit extract ameliorate fat amassment and serum TNF-α in high-fat diet-induced obese rats.

  Asian Pacific journal of tropical medicine 20120901

• Oral aphthous ulcers associated with orlistat.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120901

• Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat.

  International journal of oncology 20120801

• Assessment of the mutagenic, recombinagenic and carcinogenic potential of orlistat in somatic cells of Drosophila melanogaster.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120801

• Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia.

  Anticancer research 20120801

• Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments.

  Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20120801

• Assay and inhibition of diacylglycerol lipase activity.

  Bioorganic & medicinal chemistry letters 20120715

• Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120711

• Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20120702

• Central control of thermogenesis.

  Neuropharmacology 20120701

• A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.

  Metabolism: clinical and experimental 20120701

• Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism.

  Neuron 20120607

• Nutrient detection by incretin hormone secreting cells.

  Physiology & behavior 20120606

• Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.

  European journal of preventive cardiology 20120601

• Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.

  International journal of obesity (2005) 20120601

• Therapeutic and toxicologic evaluation of anti-lipogenic agents in cancer cells compared with non-neoplastic cells.

  Basic & clinical pharmacology & toxicology 20120601

• A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20120601

• Toxicity of weight loss agents.

  Journal of medical toxicology : official journal of the American College of Medical Toxicology 20120601

• Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats.

  Clinical and experimental pharmacology & physiology 20120601

• MNBA-mediated β-lactone formation: mechanistic studies and application for the asymmetric total synthesis of tetrahydrolipstatin.

  The Journal of organic chemistry 20120601

• Use of Orlistat 60 mg in the management of weight loss before bariatric surgery.

  The Annals of pharmacotherapy 20120601

• A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

  Cardiovascular drugs and therapy 20120601

• A systematic review on use of Chinese medicine and acupuncture for treatment of obesity.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20120501

• Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008.

  Annals of epidemiology 20120501

• The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.

  International journal of oncology 20120501

• Anti-obesity drugs: a review about their effects and their safety.

  Expert opinion on drug safety 20120501

• Preventive effect of embelin from embelia ribes on lipid metabolism and oxidative stress in high-fat diet-induced obesity in rats.

  Planta medica 20120501

• Very low calorie diets.

  Drug and therapeutics bulletin 20120501

• [Screening of pancreatic lipase and alpha-glucosidase inhibitors from Chinese dietary herbs].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20120501

• A new pancreatic lipase inhibitor from Broussonetia kanzinoki.

  Bioorganic & medicinal chemistry letters 20120415

• Gating the polarity of endocannabinoid-mediated synaptic plasticity by nitric oxide in the spinal locomotor network.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120411

• Synthesis and biological investigation of the β-thiolactone and β-lactam analogs of tetrahydrolipstatin.

  Organic & biomolecular chemistry 20120407

• Modeling the relationship between drug lipophilicity and potential for an interaction with orlistat.

  Journal of clinical pharmacology 20120401

• Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.

  Journal of clinical pharmacy and therapeutics 20120401

• Low HDL predicts differential blood pressure effects from two weight-loss approaches: a secondary analysis of blood pressure from a randomized, clinical weight-loss trial.

  Diabetes, obesity & metabolism 20120401

• Diabetes and hypertension: is there a common metabolic pathway?

  Current atherosclerosis reports 20120401

• Drug treatment of obesity in cardiovascular disease.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120401

• Non-systemic drugs: a critical review.

  Current pharmaceutical design 20120401

• Efficacy of orlistat 60 mg on weight loss and body fat mass in US Army soldiers.

  Journal of the Academy of Nutrition and Dietetics 20120401

• [The pharmacological treatment of obesity: past, present and future].

  Orvosi hetilap 20120311

• Medical management of metabolic dysfunction in PCOS.

  Steroids 20120310

• Elucidation and chemical modulation of sulfolipid-1 biosynthesis in Mycobacterium tuberculosis.

  The Journal of biological chemistry 20120309

• Transformation of the θ-phase in Mg-Li-Al alloys: a density functional theory study.

  Journal of molecular modeling 20120301

• The fatty acid translocase gene CD36 and lingual lipase influence oral sensitivity to fat in obese subjects.

  Journal of lipid research 20120301

• Orlistat: hepatitis and oxalate nephropathy.

  Prescrire international 20120301

• Effect of rosuvastatin on obesity-induced cardiac oxidative stress in Wistar rats--a preliminary study.

  Indian journal of experimental biology 20120301

• Binge eating and weight-related quality of life in obese adolescents.

  Nutrients 20120301

• Pharmacotherapy for weight management.

  The Journal of the Association of Physicians of India 20120301

• Design, development and optimization of self-microemulsifying drug delivery system of an anti-obesity drug.

  Journal of pharmacy & bioallied sciences 20120301

• A validated Ultra High Pressure Liquid Chromatographic method for the characterisation of confiscated illegal slimming products containing anorexics.

  Journal of pharmaceutical and biomedical analysis 20120205

• Both inflammatory and classical lipolytic pathways are involved in lipopolysaccharide-induced lipolysis in human adipocytes.

  Innate immunity 20120201

• Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer.

  PLoS computational biology 20120201

• Anti-Obesity Drugs: A Review about Their Effects and Safety.

  Diabetes & metabolism journal 20120201

• Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20120101

• Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats.

  Toxicology mechanisms and methods 20120101

• Phospholipase A2 mediates apolipoprotein-independent uptake of chylomicron remnant-like particles by human macrophages.

  International journal of vascular medicine 20120101

• TLC bioautographic method for detecting lipase inhibitors.

  Phytochemical analysis : PCA 20120101

• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

  BMJ (Clinical research ed.) 20120101

• Vinegar-Baked Radix Bupleuri Regulates Lipid Disorders via a Pathway Dependent on Peroxisome-Proliferator-Activated Receptor-α in High-Fat-Diet-Induced Obese Rats.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Behavioral therapy for management of obesity.

  Indian journal of endocrinology and metabolism 20120101

• Preventive pharmacotherapy in type 2 diabetes mellitus.

  Indian journal of endocrinology and metabolism 20120101

• Metabolic syndrome in the Mediterranean region: Current status.

  Indian journal of endocrinology and metabolism 20120101

• Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study.

  Indian journal of endocrinology and metabolism 20120101

• Insulin detemir for the treatment of obese patients with type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Inhibition of adipogenesis and induction of apoptosis and lipolysis by stem bromelain in 3T3-L1 adipocytes.

  PloS one 20120101

• Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4.

  PloS one 20120101

• What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

  Health technology assessment (Winchester, England) 20120101

• Developmental regulation of CB1-mediated spike-time dependent depression at immature mossy fiber-CA3 synapses.

  Scientific reports 20120101

• Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.

  Gut and liver 20120101

• Screening of crude plant extracts with anti-obesity activity.

  International journal of molecular sciences 20120101

• Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review.

  BMC psychiatry 20120101

• The influence of incretin mimetics on cardiovascular risk factors in diabetes.

  ISRN endocrinology 20120101

• Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma.

  PloS one 20120101

• Childhood obesity: a global public health crisis.

  International journal of preventive medicine 20120101

• Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical Trial.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study.

  BMJ open 20120101

• Vitamin D: The 'sunshine' vitamin.

  Journal of pharmacology & pharmacotherapeutics 20120101

• Pharmacological management of binge eating disorder: current and emerging treatment options.

  Therapeutics and clinical risk management 20120101

• Plants' metabolites as potential antiobesity agents.

  TheScientificWorldJournal 20120101

• Cytoplasmic fungal lipases release fungicides from ultra-deformable vesicular drug carriers.

  PloS one 20120101

• Cinchonine Prevents High-Fat-Diet-Induced Obesity through Downregulation of Adipogenesis and Adipose Inflammation.

  PPAR research 20120101

• The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury.

  PPAR research 20120101

• Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

  Experimental diabetes research 20120101

• A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.

  Experimental diabetes research 20120101

• Targets for medical therapy in obesity.

  Digestive diseases (Basel, Switzerland) 20120101

• Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials.

  PloS one 20120101

• An integrated analysis of liver safety data from orlistat clinical trials.

  Obesity facts 20120101

• Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.

  Obesity facts 20120101

• Differences in the inflammatory response induced by acute pancreatitis in different white adipose tissue sites in the rat.

  PloS one 20120101

• In silico identification of potent pancreatic triacylglycerol lipase inhibitors from traditional Chinese medicine.

  PloS one 20120101

• Renal stone disease and obesity: what is important for urologists and nephrologists?

  Renal failure 20120101

• Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.

  PloS one 20120101

• MmPPOX inhibits Mycobacterium tuberculosis lipolytic enzymes belonging to the hormone-sensitive lipase family and alters mycobacterial growth.

  PloS one 20120101

• In vitro screening of medicinal plants used in Mexico as antidiabetics with glucosidase and lipase inhibitory activities.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.

  Archives of medical science : AMS 20111231

• Combined treatment strategies for unconjugated hyperbilirubinemia in Gunn rats.

  Pediatric research 20111201

• Novel strategy for the use of leptin for obesity therapy.

  Expert opinion on biological therapy 20111201

• The effects of the broad-specificity lipase inhibitor, tetrahydrolipstatin, on the growth, development and survival of the larvae of Epiphyas postvittana (Walker) (Tortricidae, Lepidoptera).

  Journal of insect physiology 20111201

• Eicosapentaenoic acid administration attenuates the pro-inflammatory properties of VLDL by decreasing its susceptibility to lipoprotein lipase in macrophages.

  Atherosclerosis 20111201

• Ahnak1 abnormally localizes in muscular dystrophies and contributes to muscle vesicle release.

  Journal of muscle research and cell motility 20111201

• Drug treatment of obesity.

  The Psychiatric clinics of North America 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Metformin: multi-faceted protection against cancer.

  Oncotarget 20111201

• A two-year randomized trial of obesity treatment in primary care practice.

  The New England journal of medicine 20111124

• Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.

  Current vascular pharmacology 20111101

• Pragmatic study of orlistat 60 mg on abdominal obesity.

  European journal of clinical nutrition 20111101

• Lightening the load? A systematic review of community pharmacy-based weight management interventions.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20111101

• Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.

  Diabetes research and clinical practice 20111101

• [Management of obesity--options, effectiveness and perspectives].

  Vnitrni lekarstvi 20111101

• Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex.

  The Journal of physiology 20111015

• Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20111012

• Study of drug concentration effects on in vitro lipolysis kinetics in medium-chain triglycerides by considering oil viscosity and surface tension.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111009

• Chemical modification and organelle-specific localization of orlistat-like natural-product-based probes.

  Chemistry, an Asian journal 20111004

• Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force.

  Annals of internal medicine 20111004

• Assessment and management of obesity in childhood and adolescence.

  Nature reviews. Gastroenterology & hepatology 20111004

• Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.

  Fundamental & clinical pharmacology 20111001

• The utility of animal models to evaluate novel anti-obesity agents.

  British journal of pharmacology 20111001

• Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.

  Archives of medical science : AMS 20111001

• Obesity: Orlistat 60 mg reduces levels of visceral adipose tissue in obese individuals.

  Nature reviews. Gastroenterology & hepatology 20110902

• Predictive significance of changes in dietary restraint in obese patients with binge eating disorder during treatment.

  The International journal of eating disorders 20110901

• The 2',4',6'-trihydroxyacetophenone isolated from Myrcia multiflora has antiobesity and mixed hypolipidemic effects with the reduction of lipid intestinal absorption.

  Planta medica 20110901

• Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.

  Obesity (Silver Spring, Md.) 20110901

• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20110901

• Chylous ascites.

  North American journal of medical sciences 20110901

• The lipogenesis pathway as a cancer target.

  Journal of medicinal chemistry 20110825

• Postprandial triglyceride-rich lipoproteins induce hepatic insulin resistance in HepG2 cells independently of their receptor-mediated cellular uptake.

  Molecular and cellular endocrinology 20110822

• Molecular characterization and identification of surrogate substrates for diacylglycerol lipase α.

  Biochemical and biophysical research communications 20110812

• Current and future drug targets in weight management.

  Pharmaceutical research 20110801

• Orlistat accentuates the fat-induced fall in blood pressure in older adults.

  The British journal of nutrition 20110801

• Evaluation of the inhibitory potential of five squaric acid derivatives against pancreatic lipase.

  Journal of enzyme inhibition and medicinal chemistry 20110801

• Cholecystokinin exerts an effect via the endocannabinoid system to inhibit GABAergic transmission in midbrain periaqueductal gray.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20110801

• Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain.

  International journal of clinical pharmacy 20110801

• Drug treatment for obesity in the post-sibutramine era.

  Drug safety 20110801

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• The use of an improved intragastric balloon technique to reduce weight in pre-obese patients--preliminary results.

  Obesity surgery 20110701

• The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.

  Journal of assisted reproduction and genetics 20110701

• Lipase activity in insect oral secretions mediates defense responses in Arabidopsis.

  Plant physiology 20110701

• Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20110701

• Obesity and dyslipidemia.

  South Dakota medicine : the journal of the South Dakota State Medical Association 20110701

• Weight reduction for non-alcoholic fatty liver disease.

  The Cochrane database of systematic reviews 20110615

• How can primary care providers manage pediatric obesity in the real world?

  Journal of the American Academy of Nurse Practitioners 20110601

• Triglycerides, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol in rats exposed to premium motor spirit fumes.

  North American journal of medical sciences 20110601

• Direct molecular detection of Mycobacterium tuberculosis complex from clinical samples - An adjunct to cultural method of laboratory diagnosis of tuberculosis.

  North American journal of medical sciences 20110601

• Pharmacotherapy for overweight/obesity in ethnic minorities and White Caucasians: a systematic review and meta-analysis.

  Diabetes, obesity & metabolism 20110501

• Comparative efficiency and safety of pharmacological approaches to the management of obesity.

  Diabetes care 20110501

• Metabolic regulation of mycobacterial growth and antibiotic sensitivity.

  PLoS biology 20110501

• Genetics of Obesity: What have we Learned?

  Current genomics 20110501

• Orlistat and acute kidney injury: an analysis of 953 patients.

  Archives of internal medicine 20110411

• Purification and biochemical characterization of digestive lipase in whiteleg shrimp.

  Marine biotechnology (New York, N.Y.) 20110401

• Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo.

  International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity 20110401

• Watching intracellular lipolysis in mycobacteria using time lapse fluorescence microscopy.

  Biochimica et biophysica acta 20110401

• Comparison of APPI, APCI and ESI for the LC-MS/MS analysis of bezafibrate, cyclophosphamide, enalapril, methotrexate and orlistat in municipal wastewater.

  Journal of mass spectrometry : JMS 20110401

• Effect of Argyreia speciosa root extract on cafeteria diet-induced obesity in rats.

  Indian journal of pharmacology 20110401

• [Dyspeptic syndrome associated with antidiabetic therapy].

  Vnitrni lekarstvi 20110401

• Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.

  Journal of psychopharmacology (Oxford, England) 20110301

• Acute lower limb ischemia as a triggering condition in hypoxic hepatitis: a study of five cases.

  Journal of clinical gastroenterology 20110301

• Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.

  The Journal of clinical psychiatry 20110301

• JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner.

  The Journal of pharmacology and experimental therapeutics 20110301

• Enhancement of pancreatic lipase inhibitory activity of curcumin by radiolytic transformation.

  Bioorganic & medicinal chemistry letters 20110301

• A Phellinus baumii extract reduces obesity in high-fat diet-fed mice and absorption of triglyceride in lipid-loaded mice.

  Journal of medicinal food 20110301

• Inhibition of SREBP1 sensitizes cells to death ligands.

  Oncotarget 20110301

• Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.

  Expert review of cardiovascular therapy 20110301

• [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].

  Ugeskrift for laeger 20110221

• Visualizing inhibition of fatty acid synthase through mass spectrometric analysis of mitochondria from melanoma cells.

  Rapid communications in mass spectrometry : RCM 20110215

• Rise and fall of anti-obesity drugs.

  World journal of diabetes 20110215

• Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis.

  Laboratory investigation; a journal of technical methods and pathology 20110201

• Normal postprandial nonesterified fatty acid uptake in muscles despite increased circulating fatty acids in type 2 diabetes.

  Diabetes 20110201

• Pharmacotherapy for obese adolescents.

  Pediatric clinics of North America 20110201

• vanishing tassel2 encodes a grass-specific tryptophan aminotransferase required for vegetative and reproductive development in maize.

  The Plant cell 20110201

• Inhibitory effects of corni fructus extract on angiogenesis and adipogenesis.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20110201

• Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women.

  Journal of endocrinological investigation 20110201

• Pharmacologic treatment of pediatric obesity.

  Canadian family physician Medecin de famille canadien 20110201

• Weight loss in animals and humans treated with 'weighlevel', a combination of four medicinal plants used in traditional arabic and islamic medicine.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Refsum's Disease-Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder.

  Journal of obesity 20110101

• Weight considerations in pharmacotherapy for type 2 diabetes.

  Journal of obesity 20110101

• Anti-inflammatory nutrition as a pharmacological approach to treat obesity.

  Journal of obesity 20110101

• Purification and characterization of an intracellular lipase from pleopods of whiteleg shrimp (Litopenaeus vannamei).

  Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 20110101

• Identification of clinically used drugs that activate pregnane X receptors.

  Drug metabolism and disposition: the biological fate of chemicals 20110101

• Taking Orlistat: Predicting Weight Loss over 6 Months.

  Journal of obesity 20110101

• Canadian Physicians' Use of Antiobesity Drugs and Their Referral Patterns to Weight Management Programs or Providers: The SOCCER Study.

  Journal of obesity 20110101

• Standards of medical care in diabetes--2011.

  Diabetes care 20110101

• Pharmacotherapies for obesity: past, current, and future therapies.

  Journal of obesity 20110101

• Pharmacological treatment of obesity in patients with polycystic ovary syndrome.

  Journal of obesity 20110101

• The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.

  Journal of obesity 20110101

• Pharmacological treatment of obesity in children and adolescents: present and future.

  Journal of obesity 20110101

• Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.

  Lipids in health and disease 20110101

• Impact of orlistat-induced weight loss on diastolic function and heart rate variability in severely obese subjects with diabetes.

  Journal of obesity 20110101

• The use of lorcaserin in the management of obesity: a critical appraisal.

  Drug design, development and therapy 20110101

• 'The metabolic syndrome... is dead': these reports are an exaggeration.

  Cardiovascular diabetology 20110101

• Pharmacological and non-pharmacological interventions to influence adipose tissue function.

  Cardiovascular diabetology 20110101

• Health state preferences associated with weight status in children and adolescents.

  BMC pediatrics 20110101

• Endocannabinoids generated by Ca2+ or by metabotropic glutamate receptors appear to arise from different pools of diacylglycerol lipase.

  PloS one 20110101

• AMPK as Target for Intervention in Childhood and Adolescent Obesity.

  Journal of obesity 20110101

• Weight gain, obesity, and psychotropic prescribing.

  Journal of obesity 20110101

• Obesity and weight management in the elderly.

  British medical bulletin 20110101

• The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.

  Endocrine journal 20110101

• Present and future: pharmacologic treatment of obesity.

  Journal of obesity 20110101

• Public health campaigns and obesity - a critique.

  BMC public health 20110101

• New Year's resolutions to lose weight--dreams and reality.

  Obesity facts 20110101

• Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders.

  Nutrition journal 20110101

• Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.

  Cardiology research and practice 20110101

• Obesity in adults.

  BMJ clinical evidence 20110101

• Pharmacology in health foods:merits and demerits of food with health claims for the prevention of metabolic syndrome.

  Journal of pharmacological sciences 20110101

• Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.

  The Indian journal of tuberculosis 20110101

• The use of serotonergic drugs to treat obesity--is there any hope?

  Drug design, development and therapy 20110101

• Metabolic syndrome and renal injury.

  Cardiology research and practice 20110101

• Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review.

  The international journal of behavioral nutrition and physical activity 20110101

• Mycobacterium tuberculosis induces an atypical cell death mode to escape from infected macrophages.

  PloS one 20110101

• The Effects of Very-Low-Calorie Diets on HDL: A Review.

  Cholesterol 20110101

• [Update on current care guidelines: management of adult obesity].

  Duodecim; laaketieteellinen aikakauskirja 20110101

• High extracellular Ca2+ stimulates Ca2+-activated Cl- currents in frog parathyroid cells through the mediation of arachidonic acid cascade.

  PloS one 20110101

• Vitamin C-induced oxalate nephropathy.

  International journal of nephrology 20110101

• Reduction in BMI z-score and improvement in cardiometabolic risk factors in obese children and adolescents. The Oslo Adiposity Intervention Study - a hospital/public health nurse combined treatment.

  BMC pediatrics 20110101

• Impact of waist circumference reduction on cardiovascular risk in treated obese subjects.

  Cirugia y cirujanos 20110101

• Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up study.

  BMJ (Clinical research ed.) 20110101

• The inhibition of lipase and glucosidase activities by acacia polyphenol.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

  The open cardiovascular medicine journal 20110101

• Awareness of Abdominal Adiposity as a Cardiometabolic Risk Factor (The 5A Study): Mexico.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV.

  Virology journal 20110101

• Formulation and evaluation of Bacillus coagulans-loaded hypromellose mucoadhesive microspheres.

  International journal of nanomedicine 20110101

• Orlistat and obesity: be aware of lichenoid drug eruption.

  European journal of dermatology : EJD 20110101

• Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?

  Journal of pharmacy & bioallied sciences 20110101

• Multi-factorial approach associated with a new 'on/off' Orlistat® use in a weight loss maintenance programme: 4 years follow-up.

  Obesity facts 20110101

• Sickle cell disease and venous thromboembolism.

  Mediterranean journal of hematology and infectious diseases 20110101

• Preparation and in vitro Characterization of Porous Carrier-Based Glipizide Floating Microspheres for Gastric Delivery.

  Journal of young pharmacists : JYP 20110101

• Evaluation of efficacy and safety of orlistat in obese patients.

  Indian journal of endocrinology and metabolism 20110101

• From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

  Experimental diabetes research 20110101

• VLDL hydrolysis by hepatic lipase regulates PPARδ transcriptional responses.

  PloS one 20110101

• Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

  The open cardiovascular medicine journal 20110101

• Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.

  BMC pharmacology 20110101

• Genetics of childhood obesity.

  Journal of obesity 20110101

• Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation.

  Journal of lipids 20110101

• Acute Immobilization Stress Modulate GABA Release from Rat Olfactory Bulb: Involvement of Endocannabinoids-Cannabinoids and Acute Stress Modulate GABA Release.

  International journal of cell biology 20110101

• Usage, risk, and benefit of weight-loss drugs in primary care.

  Journal of obesity 20110101

• Predictors of weight loss and maintenance in patients treated with antiobesity drugs.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• The occurrence of left ventricular hypertrophy in normotensive individuals in a community setting in North-East Trinidad.

  Vascular health and risk management 20110101

• Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.

  PloS one 20110101

• South Yorkshire Cohort: a 'cohort trials facility' study of health and weight - protocol for the recruitment phase.

  BMC public health 20110101

• High-throughput screening of Australian marine organism extracts for bioactive molecules affecting the cellular storage of neutral lipids.

  PloS one 20110101

• Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

  Nutricion hospitalaria 20110101

• Gestational diabetes mellitus: A window of opportunity.

  Indian journal of endocrinology and metabolism 20110101

• Acute cholecystits leading to ischemic ECG changes in a patient with no underlying cardiac disease.

  JSLS : Journal of the Society of Laparoendoscopic Surgeons 20110101

• Reliable Drosophila body fat quantification by a coupled colorimetric assay.

  PloS one 20110101

• Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review.

  Lipids in health and disease 20110101

• Preparation and characterization of a coacervate extended-release microparticulate delivery system for Lactobacillus rhamnosus.

  International journal of nanomedicine 20110101

• Recent progress in the study of brown adipose tissue.

  Cell & bioscience 20110101

• Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.

  PloS one 20110101

• Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.

  Open medicine : a peer-reviewed, independent, open-access journal 20110101

• Cost-effectiveness of pharmacotherapy to reduce obesity.

  PloS one 20110101

• Short-term outcome and quality of life of endoscopically placed gastric balloon and laparoscopic adjustable gastric band.

  Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20110101

• A review of posttraumatic bowel injuries in ibadan.

  ISRN surgery 20110101

• Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance.

  Lipids in health and disease 20110101

• Using personality as a predictor of diet induced weight loss and weight management.

  The international journal of behavioral nutrition and physical activity 20110101

• Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus - results from a randomised, controlled trial.

  BMC public health 20110101

• Selection of orlistat as a potential inhibitor for lipase from Candida species.

  Bioinformation 20110101

• Management of diabetes across the course of disease: minimizing obesity-associated complications.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.

  Journal of translational medicine 20110101

• The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women.

  International journal of endocrinology 20110101

• Obesity in arabic-speaking countries.

  Journal of obesity 20110101

• Location, location, location: Beneficial effects of autologous fat transplantation.

  Scientific reports 20110101

• Effect of orlistat on lipid peroxidation, Na+, K+ ATPase, glutathione and serotonin in rat brain.

  Proceedings of the Western Pharmacology Society 20110101

• Natural products and body weight control.

  North American journal of medical sciences 20110101

• Preparation and gamma scintigraphic evaluation of colon specific pellets of ketoprofen prepared by powder layering technology.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Preparation and evaluation of sustained release microballoons of propranolol.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Antiobesity effect of Stellaria media against drug induced obesity in Swiss albino mice.

  Ayu 20110101

• Pharmacologic treatment of obesity.

  Journal of obesity 20110101

• Slim spoils for obesity drugs.

  Nature 20101216

• Carbohydrate and fat digestion is necessary for maximal suppression of total plasma ghrelin in healthy adults.

  Appetite 20101201

• Cardiovascular co-medication among users of antiobesity drugs: a population-based study.

  Pharmacy world & science : PWS 20101201

• The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation.

  Glia 20101201

• Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons.

  Endocrinology 20101201

• Pharmacological treatment of obesity in children and adolescents: current status and perspectives.

  Expert opinion on pharmacotherapy 20101201

• Dietary advanced glycation end products and aging.

  Nutrients 20101201

• Click-based synthesis and proteomic profiling of lipstatin analogues.

  Chemical communications (Cambridge, England) 20101128

• Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20101102

• Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20101101

• Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia.

  Current vascular pharmacology 20101101

• Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance.

  Obesity (Silver Spring, Md.) 20101101

• Purification and biochemical characterization of an acid-stable lipase from the pyloric caeca of sardine (Sardinella aurita).

  Applied biochemistry and biotechnology 20101101

• Managing childhood obesity: when lifestyle change is not enough.

  Diabetes, obesity & metabolism 20101101

• Obesity in children & adolescents.

  The Indian journal of medical research 20101101

• Orlistat without a prescription. The SPC now contains more situations where patients are advised to consult a doctor.

  Prescrire international 20101101

• Investigation of Orlistat effects on PXR activation and CYP3A4 expression in primary human hepatocytes and human intestinal LS174T cells.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101009

• Fatty acids increase glucose uptake and metabolism in C2C12 myoblasts stably transfected with human lipoprotein lipase.

  American journal of physiology. Endocrinology and metabolism 20101001

• Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes.

  Diabetes care 20101001

• Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D).

  Diabetes care 20101001

• Acute stimulation of white adipocyte respiration by PKA-induced lipolysis.

  Diabetes 20101001

• Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes.

  European journal of endocrinology 20101001

• Possible anti-obesity therapeutics from nature--a review.

  Phytochemistry 20101001

• Combination of fenofibrate with non-statin drug regimens.

  Current pharmaceutical design 20101001

• [Treatment of an obese diabetic].

  Vnitrni lekarstvi 20101001

• Tetrahydrolipstatin inhibition, functional analyses, and three-dimensional structure of a lipase essential for mycobacterial viability.

  The Journal of biological chemistry 20100924

• Weight loss maintenance.

  American family physician 20100915

• Endocannabinoid-mediated synaptically evoked suppression of GABAergic transmission in the cerebellar cortex.

  Neuroscience 20100901

• World Congress on the Insulin Resistance Syndrome, 2009: the kidney, the liver, and insulin resistance.

  Diabetes care 20100901

• Fat attack.

  Scientific American 20100901

• Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition.

  International journal of pharmaceutics 20100830

• Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20100801

• Morbidly obese patients--who undergoes bariatric surgery?

  Obesity surgery 20100801

• Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.

  Expert opinion on pharmacotherapy 20100801

• [Therapy of obesity with liraglutide. NN8022-1807 study].

  Der Internist 20100801

• The assessment of side effects of health recommendations given to youth in general and children and adolescents with obesity.

  Obesity facts 20100801

• Pharmaceutical quality of nine generic orlistat products compared with Xenical(r).

  Obesity facts 20100801

• Therapeutic approaches to obesity.

  Current treatment options in cardiovascular medicine 20100801

• Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.

  International journal of environmental research and public health 20100801

• The role of acyl-coenzyme A carboxylase complex in lipstatin biosynthesis of Streptomyces toxytricini.

  Applied microbiology and biotechnology 20100701

• GABA modulates development of cerebellar Purkinje cell dendrites under control of endocannabinoid signaling.

  Journal of neurochemistry 20100701

• A prevalence study and description of alli use by patients with eating disorders.

  The International journal of eating disorders 20100701

• Over-the-counter weight loss with orlistat?

  Evidence-based nursing 20100701

• Is visceral fat responsible for the metabolic abnormalities associated with obesity?: implications of omentectomy.

  Diabetes care 20100701

• Office-based strategies for the management of obesity.

  American family physician 20100615

• An orlistat 'overdose' in a child.

  Irish journal of medical science 20100601

• Two cutinase-like proteins secreted by Mycobacterium tuberculosis show very different lipolytic activities reflecting their physiological function.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20100601

• Physiological parameters governing the action of pancreatic lipase.

  Nutrition research reviews 20100601

• Gelucire 44/14 improves fat absorption in rats with impaired lipolysis.

  Biochimica et biophysica acta 20100601

• Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes.

  Diabetes care 20100601

• Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100601

• Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100601

• Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.

  Minerva gastroenterologica e dietologica 20100601

• Diabesity: therapeutic options.

  Diabetes, obesity & metabolism 20100601

• Low-carbohydrate ketogenic diet and the combination of orlistat with a low-fat diet lead to comparable improvements in weight and blood lipids, but LCKD more beneficial for blood pressure.

  Evidence-based medicine 20100601

• Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic.

  Drugs & aging 20100601

• Reversible serum carcinoembryogenic antigen (CEA) elevation due to orlistat use: A case report.

  Clinics (Sao Paulo, Brazil) 20100601

• Orlistat without a prescription: drug interactions, pancreatitis and kidney disorders.

  Prescrire international 20100601

• Pharmacological approaches for management of child and adolescent obesity.

  Journal of clinical medicine research 20100601

• Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.

  Diabetologia 20100501

• Fatty acid synthesis is a therapeutic target in human liposarcoma.

  International journal of oncology 20100501

• The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.

  Lipids 20100501

• The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.

  Diabetes, obesity & metabolism 20100501

• Managing type 2 diabetes: balancing HbA1c and body weight.

  Postgraduate medicine 20100501

• The skinny on fat.

  International journal of dental hygiene 20100501

• Weight loss in obese patients with chronic kidney disease: who and how?

  Journal of renal care 20100501

• Combination drug treatment in patients with non-alcoholic fatty liver disease.

  World journal of hepatology 20100427

• A concise, phosphate-mediated approach to the total synthesis of (-)-tetrahydrolipstatin.

  Organic letters 20100402

• Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice.

  International journal of obesity (2005) 20100401

• I've read that the diet drug orlistat may cause liver problems. Should I stop taking it?

  Mayo Clinic women's healthsource 20100401

• Fatty acid synthase as a potential therapeutic target in cancer.

  Future oncology (London, England) 20100401

• A European evidence-based guideline for the prevention of type 2 diabetes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100401

• Combination drugs for treating obesity.

  Current diabetes reports 20100401

• Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.

  Diabetic medicine : a journal of the British Diabetic Association 20100401

• Computed tomography study of the effect of orlistat on visceral adipose tissue volume in obese subjects.

  The Israel Medical Association journal : IMAJ 20100401

• [Current treatment of obesity].

  Orvosi hetilap 20100321

• Combination drug treatment in obese diabetic patients.

  World journal of diabetes 20100315

• Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.

  Diabetes care 20100301

• Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study.

  Pharmacoepidemiology and drug safety 20100301

• Negotiating the boundary between medicine and consumer culture: online marketing of nutrigenetic tests.

  Social science & medicine (1982) 20100301

• Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes.

  Diabetes 20100301

• Weight loss and blood pressure normalization: the relevance of early interventions in hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100301

• Peptides from purified soybean beta-conglycinin inhibit fatty acid synthase by interaction with the thioesterase catalytic domain.

  The FEBS journal 20100301

• Pharmacologic therapies for obesity.

  Gastroenterology clinics of North America 20100301

• Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary inhibitory connections in mouse hippocampus.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100217

• Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity.

  Drugs 20100212

• Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20100201

• Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion.

  The Journal of clinical endocrinology and metabolism 20100201

• Pathogenesis of non-alcoholic fatty liver disease.

  QJM : monthly journal of the Association of Physicians 20100201

• Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.

  Pediatrics 20100201

• Incretin concepts.

  Diabetes care 20100201

• Luminal influences to orchestrate gastroenterological hormone secretion: the fat, long-chain Fatty Acid, cholecystokinin, glucagon-like Peptide 1 axis.

  The Journal of clinical endocrinology and metabolism 20100201

• Lipase inhibitor orlistat decreases incorporation of eicosapentaenoic and docosahexaenoic acids in rat tissues.

  Nutrition research (New York, N.Y.) 20100201

• A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss.

  Archives of internal medicine 20100125

• Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study.

  Archives of internal medicine 20100125

• Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities.

  Journal of the American Chemical Society 20100120

• Evolution of stability in a cold-active enzyme elicits specificity relaxation and highlights substrate-related effects on temperature adaptation.

  Journal of molecular biology 20100108

• Acute pancreatitis following orlistat therapy: report of two cases.

  JOP : Journal of the pancreas 20100108

• Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy.

  British journal of cancer 20100105

• Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.

  The Journal of clinical investigation 20100104

• Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

  Obesity (Silver Spring, Md.) 20100101

• Trends in and patterns of obesity reduction medication use in an insured cohort.

  Obesity (Silver Spring, Md.) 20100101

• Many Americans have pre-diabetes and should be considered for metformin therapy.

  Diabetes care 20100101

• Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20100101

• Standards of medical care in diabetes--2010.

  Diabetes care 20100101

• Analysis of the UK recommendations on obesity based on a proposed implementation framework.

  BMC public health 20100101

• Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study.

  Lipids in health and disease 20100101

• The use of LeptiCore in reducing fat gain and managing weight loss in patients with metabolic syndrome.

  Lipids in health and disease 20100101

• Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients.

  Mediators of inflammation 20100101

• Elevated endotoxin levels in non-alcoholic fatty liver disease.

  Journal of inflammation (London, England) 20100101

• [Simultaneous determination of rimonabant and orlistat illegally added in the weight-loss functional foods by high performance liquid chromatography-tandem mass spectrometry].

  Se pu = Chinese journal of chromatography 20100101

• Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism.

  Lipids in health and disease 20100101

• Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.

  Journal of oncology 20100101

• Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice.

  Trials 20100101

• Disassociated relation between plasma tumor necrosis factor-alpha, interleukin-6 and increased body weight in Amerindian women: A long-term prospective study of natural body weight variation and impaired glucose tolerance.

  Diabetology & metabolic syndrome 20100101

• Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects.

  PloS one 20100101

• A 2-year multifactor approach of weight loss maintenance.

  Eating and weight disorders : EWD 20100101

• Genomic insights into early-onset obesity.

  Genome medicine 20100101

• Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.

  BMJ (Clinical research ed.) 20100101

• Expediting systematic reviews: methods and implications of rapid reviews.

  Implementation science : IS 20100101

• Validity of claims made in weight management research: a narrative review of dietetic articles.

  Nutrition journal 20100101

• Living Well with Diabetes: a randomized controlled trial of a telephone-delivered intervention for maintenance of weight loss, physical activity and glycaemic control in adults with type 2 diabetes.

  BMC public health 20100101

• Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.

  Endocrine journal 20100101

• Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment.

  Diabetology & metabolic syndrome 20100101

• Self-Reported Psychosocial Health in Obese Patients before and after Weight Loss.

  Journal of obesity 20100101

• Orlistat and calcium oxalate crystalluria: an association that needs consideration.

  Renal failure 20100101

• Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

  Vascular health and risk management 20100101

• Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

  Vascular health and risk management 20100101

• Effect of orlistat-assisted weight loss on endothelium-dependent vasodilation in obese Chinese subjects with hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

• Identification of novel inhibitors of dietary lipid absorption using zebrafish.

  PloS one 20100101

• Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.

  Therapeutics and clinical risk management 20100101

• Preventing disease through opportunistic, rapid engagement by primary care teams using behaviour change counselling (PRE-EMPT): protocol for a general practice-based cluster randomised trial.

  BMC family practice 20100101

• A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients.

  PloS one 20100101

• Rising burden of obesity in Asia.

  Journal of obesity 20100101

• Efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patients.

  Journal of obesity 20100101

• Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial.

  BMJ (Clinical research ed.) 20100101

• Trial Protocol: randomised controlled trial of the effects of very low calorie diet, modest dietary restriction, and sequential behavioural programme on hunger, urges to smoke, abstinence and weight gain in overweight smokers stopping smoking.

  Trials 20100101

• The Alberta population-based prospective evaluation of the quality of life outcomes and economic impact of bariatric surgery (APPLES) study: background, design and rationale.

  BMC health services research 20100101

• Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study.

  Vascular health and risk management 20100101

• Medical therapy for obesity.

  The Mount Sinai journal of medicine, New York 20100101

• Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis.

  BMC public health 20100101

• Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice.

  PloS one 20100101

• Oral and gastrointestinal sensing of dietary fat and appetite regulation in humans: modification by diet and obesity.

  Frontiers in neuroscience 20100101

• Liraglutide in the management of type 2 diabetes.

  Drug design, development and therapy 20100101

• The impact of female obesity on the outcome of fertility treatment.

  Journal of human reproductive sciences 20100101

• Lifestyle drugs: concept and impact on society.

  Indian journal of pharmaceutical sciences 20100101

• Maintenance of weight loss in adolescents: current status and future directions.

  Journal of obesity 20100101

• Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.

  Mens sana monographs 20100101

• Metabolic syndrome and cardiovascular risk.

  Journal of family & community medicine 20100101

• A practical discussion to avoid common pitfalls when constructing multiple choice questions items.

  Journal of family & community medicine 20100101

• Tackling obesity: new therapeutic agents for assisted weight loss.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Emerging role of GLP-1 receptor agonists in the treatment of obesity.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Lifestyle modification in the management of the metabolic syndrome: achievements and challenges.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Childhood obesity.

  Indian journal of endocrinology and metabolism 20100101

• Clinical and economic considerations of antiobesity treatment: a review of orlistat.

  ClinicoEconomics and outcomes research : CEOR 20100101

• Approaches to the pharmacological treatment of obesity.

  Expert review of clinical pharmacology 20100101

• Colonic cancer in adolescents. A report of three cases.

  Rare tumors 20091228

• Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.

  Journal of cardiovascular pharmacology and therapeutics 20091201

• Pharmacotherapy for obesity.

  British journal of clinical pharmacology 20091201

• Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.

  British journal of clinical pharmacology 20091201

• Recent concepts of pharmacotherapy and bariatric surgery for childhood obesity: an overview.

  Pediatric endocrinology reviews : PER 20091201

• A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.

  Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20091201

• Therapy of nonalcoholic fatty liver disease: current status.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20091201

• Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

  Lancet (London, England) 20091107

• Gastrointestinal hormones and weight management.

  Lancet (London, England) 20091107

• Pattern of orlistat exposures in children aged 5 years or less.

  The Journal of emergency medicine 20091101

• Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20091101

• Therapeutic potential of lipase inhibitor orlistat in Alzheimer's disease.

  Medical hypotheses 20091101

• Identification and biochemical characterization of a GDSL-motif carboxylester hydrolase from Carica papaya latex.

  Biochimica et biophysica acta 20091101

• Comparing clinician knowledge and online information regarding Alli (Orlistat).

  International journal of medical informatics 20091101

• Pharmacologic therapy of non-alcoholic steatohepatitis.

  Clinics in liver disease 20091101

• Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy.

  Diabetes care 20091101

• Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin.

  Diabetes care 20091101

• Obesity in the elderly diabetic patient: is weight loss beneficial? No.

  Diabetes care 20091101

• Over-the-counter weight loss with orlistat?

  Drug and therapeutics bulletin 20091101

• Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women.

  Journal of clinical biochemistry and nutrition 20091101

• Orlistat: current status in clinical therapeutics.

  Expert opinion on drug safety 20091101

• What are the risks and the benefits of current and emerging weight-loss medications?

  Current diabetes reports 20091001

• Rimonabant for the treatment of overweight and obese people.

  Health technology assessment (Winchester, England) 20091001

• [A comparison of the efficacy and safety of domestic orlistat and imported orlistat in Chinese overweight and obese patients].

  Zhonghua nei ke za zhi 20091001

• How physician obesity specialists use drugs to treat obesity.

  Obesity (Silver Spring, Md.) 20090901

• Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20090901

• Metformin for obesity in children and adolescents: a systematic review.

  Diabetes care 20090901

• Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.

  Diabetes care 20090901

• Pharmacotherapy in pediatric obesity: current agents and future directions.

  Reviews in endocrine & metabolic disorders 20090901

• Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease?

  International journal of clinical practice 20090901

• Medications for obesity: mechanisms and applications.

  Clinics in chest medicine 20090901

• Taeyeumjoweetang Affects Body Weight and Obesity-related Genes in Mice.

  Evidence-based complementary and alternative medicine : eCAM 20090901

• Effects of obesity reduction on cardiovascular risk factors: comparison of individual and group treatment--substudy of the Croatian Healthy Weight Loss Programme.

  Collegium antropologicum 20090901

• Effect of orlistat on the total ghrelin and leptin levels in obese patients.

  Journal of physiology and biochemistry 20090901

• Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling.

  Synapse (New York, N.Y.) 20090801

• Deletion of PKCepsilon selectively enhances the amplifying pathways of glucose-stimulated insulin secretion via increased lipolysis in mouse beta-cells.

  Diabetes 20090801

• Not glutamate but endocannabinoids mediate retrograde suppression of cerebellar parallel fiber to Purkinje cell synaptic transmission in young adult rodents.

  Neuropharmacology 20090801

• Long-term effects of weight-reducing drugs in hypertensive patients.

  The Cochrane database of systematic reviews 20090708

• Effect of antiobesity medications in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20090701

• Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.

  Metabolism: clinical and experimental 20090701

• Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs.

  Pharmacoepidemiology and drug safety 20090701

• Orlistat for overweight subjects with nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20090701

• Anti-lipase and lipolytic activities of ursolic acid isolated from the roots of Actinidia arguta.

  Archives of pharmacal research 20090701

• [Statement about the medical and surgical treatment of overweight and obesity].

  Revista medica de Chile 20090701

• Asymmetric synthesis of anti-aldol segments via a nonaldol route: synthetic applications to statines and (-)-tetrahydrolipstatin.

  The Journal of organic chemistry 20090619

• Metabolic syndrome in the pediatric population: a short overview.

  Pediatric reports 20090608

• The effects of diet and orlistat on body weight and lipid profiles in high risk Chinese patients with coronary artery disease, obesity and hypercholesterolemia.

  Irish journal of medical science 20090601

• Short-term exercise training does not stimulate skeletal muscle ATP synthesis in relatives of humans with type 2 diabetes.

  Diabetes 20090601

• Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo.

  Lipids 20090601

• The acute effect of Orlistat on dietary glycotoxins in diabetics and healthy women.

  Minerva endocrinologica 20090601

• Orlistat for overweight subjects with nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20090601

• Orlistat half the dose without a prescription: new status. In excess body weight: often uncomfortable and don't expect miracles. Frequent gastrointestinal disturbances for a weight loss of a few kilos. Better to encourage dietary measures, exercise and individualised support.

  Prescrire international 20090601

• [Management of overweight persons in the public pharmacy].

  Journal de pharmacie de Belgique 20090601

• [Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].

  Journal de pharmacie de Belgique 20090601

• [Determination of lipase activity by gas chromatography].

  Yao xue xue bao = Acta pharmaceutica Sinica 20090601

• Trp-107 and trp-253 account for the increased steady state fluorescence that accompanies the conformational change in human pancreatic triglyceride lipase induced by tetrahydrolipstatin and bile salt.

  The Journal of biological chemistry 20090522

• [Fat blockers now without a prescription--without diet the reducing pill has little effect (interview by Dr. Judith Neumaier)].

  MMW Fortschritte der Medizin 20090514

• De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy.

  British journal of cancer 20090505

• Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis.

  Cellular signalling 20090501

• Hydrolysis of tumor cell lipids after CTL-mediated death.

  International immunology 20090501

• Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20090501

• Exploring the effects of orlistat and guidance on its use to achieve weight loss in patients.

  Nursing times 20090501

• An RCT of metformin versus orlistat for the management of obese anovulatory women.

  Human reproduction (Oxford, England) 20090401

• One-year weight losses in the Look AHEAD study: factors associated with success.

  Obesity (Silver Spring, Md.) 20090401

• Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.

  Diabetes, obesity & metabolism 20090401

• Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.

  International journal of clinical practice 20090401

• An unusual complication of treatment with orlistat.

  Clinical nephrology 20090401

• Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extraction liquid chromatography coupled to polarity-switching electrospray tandem mass spectrometry.

  Journal of environmental monitoring : JEM 20090401

• Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells.

  Gut 20090301

• Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.

  American journal of physiology. Gastrointestinal and liver physiology 20090301

• Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.

  British journal of clinical pharmacology 20090301

• Caveat emptor.

  The British journal of general practice : the journal of the Royal College of General Practitioners 20090301

• Should weight-loss supplements be used for pediatric obesity?

  Canadian family physician Medecin de famille canadien 20090301

• Effects of orlistat on visceral fat after liposuction.

  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20090301

• Management of obesity in adolescents: state of art.

  Arquivos brasileiros de endocrinologia e metabologia 20090301

• The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.

  Arquivos brasileiros de endocrinologia e metabologia 20090301

• Emerging drugs for obesity therapy.

  Arquivos brasileiros de endocrinologia e metabologia 20090301

• Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.

  Clinical endocrinology 20090201

• Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients.

  Diabetes care 20090201

• Current pharmacotherapeutic concepts for the treatment of obesity in adults.

  Therapeutic advances in cardiovascular disease 20090201

• The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.

  Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 20090201

• Nurses should welcome the non-prescription obesity drug.

  Nursing times 20090201

• Pediatric obesity: looking into treatment.

  Nutrients 20090201

• Over-the-counter medicines: in whose best interests?

  Lancet (London, England) 20090131

• Interventions for treating obesity in children.

  The Cochrane database of systematic reviews 20090121

• The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice.

  Acta physiologica (Oxford, England) 20090101

• Endothelial lipase promotes apolipoprotein AI-mediated cholesterol efflux in THP-1 macrophages.

  Arteriosclerosis, thrombosis, and vascular biology 20090101

• Pharmacotherapy for eating disorders and obesity.

  Child and adolescent psychiatric clinics of North America 20090101

• Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.

  Nature chemical biology 20090101

• Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.

  Hepatology (Baltimore, Md.) 20090101

• I read with great interest the article by Hafkamp et al.

  Pediatric research 20090101

• Randomized clinical trials of weight loss maintenance: a review.

  The Journal of cardiovascular nursing 20090101

• Standards of medical care in diabetes--2009.

  Diabetes care 20090101

• Recent advances in obesity pharmacotherapy.

  Current clinical pharmacology 20090101

• Mycobacterium tuberculosis Rv3802c encodes a phospholipase/thioesterase and is inhibited by the antimycobacterial agent tetrahydrolipstatin.

  PloS one 20090101

• Obesity: pathophysiology and clinical management.

  Current medicinal chemistry 20090101

• Lipid-lowering drugs acting at the level of the gastrointestinal tract.

  Current pharmaceutical design 20090101

• Weight control behaviors in overweight/obese U.S. adults with diagnosed hypertension and diabetes.

  Cardiovascular diabetology 20090101

• Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship.

  PloS one 20090101

• Orlistat misuse as purging in a patient with binge-eating disorder.

  Psychosomatics 20090101

• A randomised controlled trial of a community-based healthy lifestyle program for overweight and obese adolescents: the Loozit study protocol.

  BMC public health 20090101

• Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study.

  BMC public health 20090101

• Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.

  Vascular health and risk management 20090101

• The use of sibutramine in the management of obesity and related disorders: an update.

  Vascular health and risk management 20090101

• Cost-effectiveness of an opportunistic screening programme and brief intervention for excessive alcohol use in primary care.

  PloS one 20090101

• p63 promotes cell survival through fatty acid synthase.

  PloS one 20090101

• [Drug treatment of obesity].

  Revue medicale de Bruxelles 20090101

• Pharmacotherapy and surgery treatment for the severely obese adolescent.

  Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners 20090101

• Kidney function and estimated vascular risk in patients with primary dyslipidemia.

  The open cardiovascular medicine journal 20090101

• Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells.

  PloS one 20090101

• Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods.

  PloS one 20090101

• Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention.

  Lipids in health and disease 20090101

• Anti-obesity agents: a focused review on the structural classification of therapeutic entities.

  Current topics in medicinal chemistry 20090101

• New trends in medicinal chemistry approaches to antiobesity therapy.

  Current topics in medicinal chemistry 20090101

• Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes.

  PloS one 20090101

• [Therapeutic options for treatment of cardiometabolic risk].

  Medicinski pregled 20090101

• Histological evaluation of AMPK signalling in primary breast cancer.

  BMC cancer 20090101

• [Obesity treatment in metabolic syndrome patients].

  Vnitrni lekarstvi 20090101

• Cost-effectiveness of a telephone-delivered intervention for physical activity and diet.

  PloS one 20090101

• What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese?

  Asia Pacific journal of clinical nutrition 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.

  BMC gastroenterology 20090101

• Assessing cost-effectiveness in obesity (ACE-obesity): an overview of the ACE approach, economic methods and cost results.

  BMC public health 20090101

• Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial.

  BMJ (Clinical research ed.) 20090101

• Evaluation of 8-week body weight control program including sea tangle (Laminaria japonica) supplementation in Korean female college students.

  Nutrition research and practice 20090101

• A comprehensive review of immunosuppression used for liver transplantation.

  Journal of transplantation 20090101

• Influence of sibutramine, orlistat and Ispaghula in reducing body weight and total body fat content in obese individuals.

  Journal of Ayub Medical College, Abbottabad : JAMC 20090101

• Is there an effective therapy available for non-alcoholic fatty liver disease?

  F1000 medicine reports 20090101

• Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Clinical approach in treatment of resistant hypertension.

  Integrated blood pressure control 20090101

• Do dietary supplements help promote weight loss?

  Journal of dietary supplements 20090101

• Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20081201

• Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model.

  International journal of cancer 20081201

• Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials.

  The Journal of clinical endocrinology and metabolism 20081201

• Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.

  International journal of obesity (2005) 20081201

• The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.

  Expert opinion on pharmacotherapy 20081201

• Triple reuptake inhibitors: the next generation of antidepressants.

  Current neuropharmacology 20081201

• Is new hope on the horizon for obesity?

  Lancet (London, England) 20081129

• Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4.

  The Journal of biological chemistry 20081114

• Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.

  Journal of medicinal chemistry 20081113

• Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray.

  Molecular pharmacology 20081101

• Influence of race, ethnicity, and culture on childhood obesity: implications for prevention and treatment: a consensus statement of Shaping America's Health and the Obesity Society.

  Diabetes care 20081101

• American College of Endocrinology Pre-Diabetes Consensus Conference: part two.

  Diabetes care 20081101

• Current and emerging therapies in nonalcoholic fatty liver disease.

  Seminars in liver disease 20081101

• Lifestyle and pharmacological approaches to weight loss: efficacy and safety.

  The Journal of clinical endocrinology and metabolism 20081101

• The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.

  Current diabetes reviews 20081101

• Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.

  The Journal of clinical endocrinology and metabolism 20081001

• Electroacupuncture in the treatment of obesity.

  Neurochemical research 20081001

• Lipases in the pancreatic beta-cell: implications for insulin secretion.

  Biochemical Society transactions 20081001

• Is rimonabant efficacious and safe in the treatment of obesity?

  Expert opinion on pharmacotherapy 20081001

• A possibly overlooked side effect of Orlistat: gastroesophageal reflux disease.

  Journal of the National Medical Association 20081001

• Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review.

  Diabetic medicine : a journal of the British Diabetic Association 20081001

• Clinical pharmacology.

  Indian journal of pharmacology 20081001

• Synthesis of novel beta-lactone inhibitors of fatty acid synthase.

  Journal of medicinal chemistry 20080911

• Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20080901

• Moderate weight loss in obese women with urinary incontinence: a prospective longitudinal study.

  International urogynecology journal and pelvic floor dysfunction 20080901

• Metabolically favorable remodeling of human adipose tissue by human adenovirus type 36.

  Diabetes 20080901

• Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease.

  Current opinion in clinical nutrition and metabolic care 20080901

• Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.

  Diabetes care 20080901

• Acute effects of orlistat on postprandial serum leptin levels in nondiabetic obese patients.

  Minerva endocrinologica 20080901

• Review and meta-analysis of pharmacotherapy for binge-eating disorder.

  Obesity (Silver Spring, Md.) 20080901

• Effectiveness of weight management programs in children and adolescents.

  Evidence report/technology assessment 20080901

• Drugs in the pipeline for the obesity market.

  Journal of diabetes science and technology 20080901

• Triple reuptake inhibitors: a premise and promise.

  Psychiatry investigation 20080901

• Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine.

  Molecular cancer therapeutics 20080801

• An update in prevention and treatment of pediatric obesity.

  World journal of pediatrics : WJP 20080801

• Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome.

  Journal of clinical lipidology 20080801

• Central carbon metabolism in the progression of mammary carcinoma.

  Breast cancer research and treatment 20080701

• Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor.

  Obesity (Silver Spring, Md.) 20080701

• The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.

  Current medical research and opinion 20080701

• Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance.

  International journal of clinical practice 20080701

• Analysis of six synthetic adulterants in herbal weight-reducing dietary supplements by LC electrospray ionization-MS.

  Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment 20080701

• Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes.

  Diabetes care 20080701

• The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.

  Postgraduate medicine 20080701

• Schizophrenia, obesity, and antipsychotic medications: what can we do?

  Postgraduate medicine 20080701

• AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance.

  The Journal of biological chemistry 20080613

• The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.

  Diabetes, obesity & metabolism 20080601

• Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.

  Diabetes, obesity & metabolism 20080601

• Orlistat and sibutramine beyond weight loss.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20080601

• Purinergic signalling in the subretinal space: a role in the communication between the retina and the RPE.

  Purinergic signalling 20080601

• Time to insulin in type-2 diabetes: high hurdles or Santiago way?

  Acta diabetologica 20080601

• Fatty acid synthase is a novel therapeutic target in multiple myeloma.

  British journal of haematology 20080601

• Pharmacotherapy for obesity in menopausal women.

  Menopause international 20080601

• Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions.

  International journal of clinical pharmacology and therapeutics 20080601

• Nutrigenomic analysis of diet-gene interactions on functional supplements for weight management.

  Current genomics 20080601

• Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

  Core evidence 20080601

• Neonatal jaundice and stool production in breast- or formula-fed term infants.

  European journal of pediatrics 20080501

• Pharmaceutical particle engineering via spray drying.

  Pharmaceutical research 20080501

• Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080501

• Regulation of fat-stimulated neurotensin secretion in healthy subjects.

  The Journal of clinical endocrinology and metabolism 20080501

• Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.

  The Journal of clinical psychiatry 20080501

• Myopathy associated with chronic orlistat consumption: a case report.

  Neuromuscular disorders : NMD 20080501

• Unsaturated fatty acids liberated from VLDL cause apoptosis in endothelial cells.

  Molecular nutrition & food research 20080501

• [Adipocytokines: implications in the prognosis and drug treatment of cardiovascular diseases].

  Revista clinica espanola 20080501

• Antipsychotic induced weight gain in schizophrenia:mechanisms and management.

  The Australian and New Zealand journal of psychiatry 20080501

• [Orlistat-induced acute pancreatitis].

  Medicina clinica 20080419

• Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.

  Fertility and sterility 20080401

• The intestine as source of cytotoxic mediators in shock: free fatty acids and degradation of lipid-binding proteins.

  American journal of physiology. Heart and circulatory physiology 20080401

• Glucose-insulin therapy, plasma substrate levels and cardiac recovery after cardiac ischemic events.

  Cardiovascular drugs and therapy 20080401

• Beta-lactam congeners of orlistat as inhibitors of fatty acid synthase.

  Bioorganic & medicinal chemistry letters 20080401

• Patient's page. Obesity and you.

  Southern medical journal 20080401

• Purification and characterization of the first reptile pancreatic lipase: the turtle.

  Pancreas 20080401

• Orlistat in the prevention of diabetes in the obese patient.

  Vascular health and risk management 20080401

• [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].

  Giornale italiano di cardiologia (2006) 20080401

• [Pharmacological therapy of obesity].

  Giornale italiano di cardiologia (2006) 20080401

• Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.

  Archives of internal medicine 20080324

• Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20080301

• Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands.

  Proteins 20080301

• Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.

  Leukemia 20080301

• Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.

  Obesity (Silver Spring, Md.) 20080301

• Are non-prescription medications needed for weight control?

  Obesity (Silver Spring, Md.) 20080301

• The future of obesity: new drugs versus lifestyle interventions.

  Expert opinion on investigational drugs 20080301

• Drug-induced crystal nephropathy: an update.

  Expert opinion on drug safety 20080301

• Efficacy of healthy weight loss program in obesity treatment: Croatian experience.

  Collegium antropologicum 20080301

• [The endocannabinoid system and treatment of obesity].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080227

• [Metabolic syndrome: jumble syndrome of obesity or specific entity? Which treatment: diet or polypill?].

  Revue medicale suisse 20080206

• Treatment of childhood obesity.

  Current opinion in endocrinology, diabetes, and obesity 20080201

• Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study.

  European journal of endocrinology 20080201

• Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial.

  Obesity (Silver Spring, Md.) 20080201

• A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction.

  Molecular cancer therapeutics 20080201

• Obesity in adults.

  BMJ clinical evidence 20080118

• Orlistat over the counter: Is it worth it?

  BMJ (Clinical research ed.) 20080105

• Orlistat over the counter: People should be free to spend their money as they wish.

  BMJ (Clinical research ed.) 20080105

• Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release.

  Neuropharmacology 20080101

• Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon.

  Journal of molecular medicine (Berlin, Germany) 20080101

• Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.

  Schizophrenia bulletin 20080101

• A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

• Economic evaluation of treatment with orlistat in Italian obese patients.

  Current medical research and opinion 20080101

• [Pharmacotherapy of obesity].

  Der Internist 20080101

• Orlistat-associated adverse effects and drug interactions: a critical review.

  Drug safety 20080101

• Protection of pancreatic beta-cells: is it feasible?

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20080101

• Obesity: a review of pathogenesis and management strategies.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20080101

• Emerging concepts in the medical and surgical treatment of obesity.

  Frontiers of hormone research 20080101

• Helping patients lose weight--what works?

  Australian family physician 20080101

• Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancer.

  International seminars in surgical oncology : ISSO 20080101

• The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trial.

  Lipids in health and disease 20080101

• Review: orlistat, sibutramine, and rimonabant reduce weight in overweight and obese persons.

  ACP journal club 20080101

• Pediatric obesity: parallels with addiction and treatment recommendations.

  Harvard review of psychiatry 20080101

• Family physician and endocrinologist coordination as the basis for diabetes care in clinical practice.

  BMC endocrine disorders 20080101

• Very-low-density lipoprotein-induced triglyceride accumulation in human mesangial cells is mainly mediated by lipoprotein lipase.

  Nephron. Physiology 20080101

• Long-term effects of lipase inhibition by orlistat on gastric emptying and orocecal transit time of a solid meal.

  Journal of gastroenterology 20080101

• A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development.

  Nutrition & metabolism 20080101

• Commercial weight loss diets meet nutrient requirements in free living adults over 8 weeks: a randomised controlled weight loss trial.

  Nutrition journal 20080101

• Vaccination against GIP for the treatment of obesity.

  PloS one 20080101

• The prince and the pauper. A tale of anticancer targeted agents.

  Molecular cancer 20080101

• PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities.

  PPAR research 20080101

• 'They all work...when you stick to them': a qualitative investigation of dieting, weight loss, and physical exercise, in obese individuals.

  Nutrition journal 20080101

• Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery.

  Clinical cornerstone 20080101

• The endocannabinoid system as a target for obesity treatment.

  Clinical cornerstone 20080101

• [Metabolic syndrome and chronic disease of the kidneys: the role of age-related androgenic deficiency. New approaches to treatment (review)].

  Terapevticheskii arkhiv 20080101

• Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance.

  BMC microbiology 20080101

• In vitro evaluation of porous carrier-based floating granular delivery system of orlistat.

  PDA journal of pharmaceutical science and technology 20080101

• Identification and treatment of prediabetes to prevent progression to type 2 diabetes.

  Clinical cornerstone 20080101

• Post-graduate CME.

  Indian journal of psychiatry 20080101

• Pancreatic lipase inhibitory activity of taraxacum officinale in vitro and in vivo.

  Nutrition research and practice 20080101

• Behaviour therapy for obesity treatment considering approved drug therapy.

  GMS health technology assessment 20080101

• Characterization of an exported monoglyceride lipase from Mycobacterium tuberculosis possibly involved in the metabolism of host cell membrane lipids.

  The Biochemical journal 20071215

• The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.

  Cancer cell 20071211

• Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

  BMJ (Clinical research ed.) 20071208

• Orlistat over the counter.

  BMJ (Clinical research ed.) 20071208

• Role of lipase in Burkholderia cepacia complex (Bcc) invasion of lung epithelial cells.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20071201

• Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial.

  Pediatric research 20071201

• Prevention of Type 2 diabetes: fact or fiction?

  Expert opinion on pharmacotherapy 20071201

• Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat.

  Journal of evaluation in clinical practice 20071201

• A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.

  Chemistry & biology 20071201

• Obesity management: update on orlistat.

  Vascular health and risk management 20071201

• Rationale for multiple risk intervention: the need to move from theory to practice.

  Vascular health and risk management 20071201

• Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity.

  Arquivos brasileiros de cardiologia 20071201

• Pharmacotherapy for obesity.

  Current atherosclerosis reports 20071201

• Treatment of non-alcoholic fatty liver disease.

  Therapeutics and clinical risk management 20071201

• [Antiobesity drugs--new limitations].

  Revue medicale suisse 20071128

• Rapid response predicts binge eating and weight loss in binge eating disorder: findings from a controlled trial of orlistat with guided self-help cognitive behavioral therapy.

  Behaviour research and therapy 20071101

• Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20071101

• The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.

  Obesity (Silver Spring, Md.) 20071101

• Lessons from 'lower' organisms: what worms, flies, and zebrafish can teach us about human energy metabolism.

  PLoS genetics 20071101

• [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].

  Postepy higieny i medycyny doswiadczalnej (Online) 20071019

• [Obesity in adults].

  Praxis 20071017

• [Recurrent unexplained lipothymia: do not forget the capillary leak syndrome].

  La Revue de medecine interne 20071001

• Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH).

  Digestive diseases and sciences 20071001

• Long-term persistence with orlistat and sibutramine in a population-based cohort.

  International journal of obesity (2005) 20071001

• Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.

  Cellular microbiology 20071001

• Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.

  Public health nutrition 20071001

• Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.

  Journal of the American Dietetic Association 20071001

• Strategies to reduce vascular risk associated with obesity.

  Current vascular pharmacology 20071001

• Comparison of different methods to assess body composition of weight loss in obese and diabetic patients.

  Diabetes research and clinical practice 20070901

• The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients.

  Clinical endocrinology 20070901

• The obesity pandemic--how did we get here?

  The Annals of pharmacotherapy 20070901

• Pharmacotherapeutic options for overweight adolescents.

  The Annals of pharmacotherapy 20070901

• Reflecting on type 2 diabetes prevention: more questions than answers!

  Diabetes, obesity & metabolism 20070901

• Acute chylous peritonitis mimicking ovarian torsion in a patient with advanced gastric carcinoma.

  Journal of Korean medical science 20070901

• [Pharmacotherapy for weight loss in patients with type 2 diabetes].

  Ugeskrift for laeger 20070813

• The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.

  Atherosclerosis 20070801

• Acute limb ischemia in elderly patients: can iloprost be useful as an adjuvant to surgery? Results from the ILAILL study.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20070801

• Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070801

• Stimulation of fecal fat excretion and the disposal of protoporphyrin in a murine model for erythropoietic protoporphyria.

  American journal of physiology. Gastrointestinal and liver physiology 20070801

• Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat.

  Nature structural & molecular biology 20070801

• Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage.

  Expert opinion on pharmacotherapy 20070801

• NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.

  Obesity (Silver Spring, Md.) 20070801

• Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk.

  Current treatment options in cardiovascular medicine 20070801

• The burden of type 2 diabetes: strategies to prevent or delay onset.

  Vascular health and risk management 20070801

• Sucrose fatty acid esters suppress pancreatic secretion accompanied by peptide YY release in pancreatico-biliary diverted rats.

  Experimental physiology 20070701

• Further biochemical characterization of human pancreatic lipase-related protein 2 expressed in yeast cells.

  Journal of lipid research 20070701

• The word is 'leakage'.

  Newsweek 20070625

• Effects of block length on the enzymatic degradation and erosion of oxazoline linked poly-epsilon-caprolactone.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20070601

• National trends in the use and costs of anti-obesity medications in England 1998-2005.

  Journal of public health (Oxford, England) 20070601

• I am about 15 lbs. overweight. Do you recommend the new over-the-counter diet pill Alli?

  The Johns Hopkins medical letter health after 50 20070601

• Weighing Alli's impact. Eating disorder patients might be tempted to abuse the first FDA-approved nonprescription diet pill.

  Behavioral healthcare 20070601

• Orlistat increases serum paraoxonase activity in obese patients.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20070501

• Visualization of 2-arachidonoylglycerol accumulation and cannabinoid CB1 receptor activity in rat brain cryosections by functional autoradiography.

  Journal of neurochemistry 20070501

• Changes in body composition with weight loss: obese subjects randomized to surgical and medical programs.

  Obesity (Silver Spring, Md.) 20070501

• Drug treatment of the overweight patient.

  Gastroenterology 20070501

• Drug treatments for obesity.

  Lancet (London, England) 20070407

• Drug treatments for obesity.

  Lancet (London, England) 20070407

• [New therapeutic aspects for the control of risk factors in obesity].

  Medicina clinica 20070407

• Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070404

• Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men.

  American journal of physiology. Regulatory, integrative and comparative physiology 20070401

• Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.

  Vascular health and risk management 20070401

• Challenges and strategies in managing cardiometabolic risk.

  The Journal of the American Osteopathic Association 20070401

• Pharmacological interventions in the prevention of type 2 diabetes.

  Current opinion in endocrinology, diabetes, and obesity 20070401

• The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity.

  The Journal of biological chemistry 20070316

• Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal.

  Regulatory peptides 20070301

• Lipases and lipolysis in the human digestive tract: where do we stand?

  Current opinion in clinical nutrition and metabolic care 20070301

• Enterohepatic circulation of organochlorine compounds: a site for nutritional intervention.

  The Journal of nutritional biochemistry 20070301

• Therapeutic options for modifying cardiometabolic risk factors.

  The American journal of medicine 20070301

• [Drug treatment in type 2 diabetes (part 2)].

  Presse medicale (Paris, France : 1983) 20070301

• Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis.

  Gut 20070301

• Comment: low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.

  The Annals of pharmacotherapy 20070301

• [Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment].

  Anales de pediatria (Barcelona, Spain : 2003) 20070301

• Changing patterns in the etiology of acute lower limb ischemia.

  International angiology : a journal of the International Union of Angiology 20070301

• Analysis of the factors affecting the success of weight reduction programs.

  Yonsei medical journal 20070227

• Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070227

• Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.

  The American journal of cardiology 20070219

• Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.

  BMJ (Clinical research ed.) 20070210

• Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070201

• Mass spectrometric evidence of covalently-bound tetrahydrolipstatin at the catalytic serine of Streptomyces rimosus lipase.

  Biochimica et biophysica acta 20070201

• Incorrect use of orlistat and sibutramine in clinical practice.

  European journal of clinical pharmacology 20070201

• The obese teen: the neuroendocrine connection.

  The American journal of nursing 20070201

• HPLC analysis of orlistat and its application to drug quality control studies.

  Chemical & pharmaceutical bulletin 20070201

• Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells.

  Cancer research 20070201

• Cardiometabolic aspects of polycystic ovarian syndrome.

  Vascular health and risk management 20070201

• Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

  Lancet (London, England) 20070106

• The obesity epidemic: current and future pharmacological treatments.

  Annual review of pharmacology and toxicology 20070101

• Simultaneous assessment of lipid classes and bile acids in human intestinal fluid by solid-phase extraction and HPLC methods.

  Journal of lipid research 20070101

• Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20070101

• Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.

  Diabetes care 20070101

• Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.

  Clinical endocrinology 20070101

• Effect of fat digestion on superior mesenteric artery blood flow in humans.

  Clinical physiology and functional imaging 20070101

• Mathematical modeling of the socalled Allis test: a field study in orthopedic confusion.

  Chiropractic & osteopathy 20070101

• Currently available drugs for the treatment of obesity: Sibutramine and orlistat.

  Mini reviews in medicinal chemistry 20070101

• The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress.

  Lipids in health and disease 20070101

• Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.

  Angiology 20070101

• Difficulties implementing a mental health guideline: an exploratory investigation using psychological theory.

  Implementation science : IS 20070101

• A new 'Alli' in weight loss.

  Current topics in medicinal chemistry 20070101

• Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer.

  BMC genomics 20070101

• Retrograde endocannabinoid inhibition of goldfish retinal cones is mediated by 2-arachidonoyl glycerol.

  Visual neuroscience 20070101

• [What do we know about obesity?].

  La Clinica terapeutica 20070101

• Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex.

  PloS one 20070101

• Anti-obesity drug use before professional treatment in Taiwan.

  Asia Pacific journal of clinical nutrition 20070101

• [Recent advances in the management of obesity].

  Revue medicale de Liege 20070101

• Improved weight management using genetic information to personalize a calorie controlled diet.

  Nutrition journal 20070101

• Over-the-counter products for weight management.

  The Alabama nurse 20070101

• Adipose gene expression prior to weight loss can differentiate and weakly predict dietary responders.

  PloS one 20070101

• [Xenical--a modern perspective drug for the treatment of obesity (review)].

  Terapevticheskii arkhiv 20070101

• Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.

  Chang Gung medical journal 20070101

• Hypolipidemic effect of Salicornia herbacea in animal model of type 2 diabetes mellitus.

  Nutrition research and practice 20070101

• Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome.

  Core evidence 20070101

• A Chinese hamster ovarian cell line imports cholesterol by high density lipoprotein degradation.

  The Journal of biological chemistry 20061215

• Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial.

  Transplant international : official journal of the European Society for Organ Transplantation 20061201

• Sibutramine for obesity in adolescents.

  Expert opinion on pharmacotherapy 20061201

• Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat.

  Epilepsia 20061201

• [Pharmacotherapy of obesity].

  Medizinische Monatsschrift fur Pharmazeuten 20061201

• Evaluation of porous carrier-based floating orlistat microspheres for gastric delivery.

  AAPS PharmSciTech 20061201

• Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.

  Eating and weight disorders : EWD 20061201

• Appetite suppression through delayed fat digestion.

  Physiology & behavior 20061130

• Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol.

  The Journal of physiology 20061115

• Safety profile of orlistat: results of a prescription-event monitoring study.

  International journal of obesity (2005) 20061101

• Orlistat: Current issues for patients with type 2 diabetes.

  Current diabetes reports 20061101

• Effects of lipase inhibition on gastric emptying and alcohol absorption in healthy subjects.

  The British journal of nutrition 20061101

• Baseline serum folate level may be a predictive factor of weight loss in a morbid-obesity-management programme.

  The British journal of nutrition 20061101

• Biologically active triterpenoid saponins from Acanthopanax senticosus.

  Journal of natural products 20061101

• Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?

  Expert review of cardiovascular therapy 20061101

• Fatty acid synthase: a novel target for antiglioma therapy.

  British journal of cancer 20061009

• [Successful treatment of obesity].

  MMW Fortschritte der Medizin 20061005

• Current and novel approaches to the drug therapy of obesity.

  European journal of clinical pharmacology 20061001

• Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.

  The Annals of pharmacotherapy 20061001

• Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat.

  Journal of internal medicine 20061001

• The community management of chylous fistula using a pancreatic lipase inhibitor (orlistat).

  The Laryngoscope 20061001

• Adherence, behavior change, and visualization: a qualitative study of the experiences of taking an obesity medication.

  Journal of psychosomatic research 20061001

• Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061001

• Rise of plasma ghrelin with weight loss is not sustained during weight maintenance.

  Obesity (Silver Spring, Md.) 20061001

• Assaying lipase activity from oil palm fruit (Elaeis guineensis Jacq.) mesocarp.

  Plant physiology and biochemistry : PPB 20061001

• [Use of orlistat (xenical) in the treatment of women with obesity and disorders of menstrual cycle].

  Georgian medical news 20061001

• Pharmacotherapy of obesity.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20061001

• Management issues in the metabolic syndrome.

  The Journal of the Association of Physicians of India 20061001

• Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: Inhibitors of fatty acid synthase.

  Organic letters 20060928

• Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling.

  Diabetologia 20060901

• The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen.

  Cancer letters 20060828

• Influences of fat restriction and lipase inhibition on gastric emptying in obesity.

  International journal of obesity (2005) 20060801

• Antiobesity action of epsilon-polylysine, a potent inhibitor of pancreatic lipase.

  Journal of lipid research 20060801

• An update on the pharmacological treatment of obesity.

  Current medical research and opinion 20060801

• Inhibition of pancreatic lipase by poloxamer 407 may provide an adjunct treatment strategy for weight loss.

  The Journal of pharmacy and pharmacology 20060801

• Severe hepatic injury caused by orlistat.

  The American journal of medicine 20060801

• Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.

  International journal of clinical practice 20060801

• Weight loss medications--where do they fit in?

  Australian family physician 20060801

• Pharmacologic treatment for obesity. Options for today...and tomorrow.

  Advance for nurse practitioners 20060801

• Rimonabant: new drug. Obesity: loss of a few kilos, many questions.

  Prescrire international 20060801

• Effect of weight loss on P wave dispersion in obese subjects.

  Obesity (Silver Spring, Md.) 20060801

• The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages.

  Journal of lipid research 20060701

• Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4.

  Bioorganic & medicinal chemistry letters 20060701

• The obesity epidemic and its cardiovascular consequences.

  Current opinion in cardiology 20060701

• Biochemical and molecular characterization of a lipase produced by Rhizopus oryzae.

  FEMS microbiology letters 20060701

• Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20060701

• Practical, catalytic, asymmetric synthesis of beta-lactones via a sequential ketene dimerization/hydrogenation process: inhibitors of the thioesterase domain of fatty acid synthase.

  The Journal of organic chemistry 20060609

• The influence of a 3-month weight reduction therapy with Orlistat on serum vitamin B12 and folic acid concentration in obese women.

  International journal of obesity (2005) 20060601

• Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.

  Obesity (Silver Spring, Md.) 20060601

• Vascular risks and management of obesity in children and adolescents.

  Vascular health and risk management 20060601

• A stability-indicating high performance liquid chromatographic assay for the determination of orlistat in capsules.

  Journal of chromatography. A 20060526

• Summaries for patients. Treating obesity: laparoscopic gastric banding versus a nonsurgical weight loss program.

  Annals of internal medicine 20060502

• Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial.

  Annals of internal medicine 20060502

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Gut peptides and the regulation of appetite.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20060501

• A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20060501

• Lichenoid eruption associated with orlistat.

  The British journal of dermatology 20060501

• Diabetes prevention: is there more to it than lifestyle changes?

  International journal of clinical practice 20060501

• Orlistat.

  Nursing times 20060501

• Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

  Current medical research and opinion 20060501

• [Determination of orlistat in health food for controlling body weight by high performance liquid chromatography/electrospray spectrometry].

  Wei sheng yan jiu = Journal of hygiene research 20060501

• [A practicing physician's view on obesity].

  Orvosi hetilap 20060402

• Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans.

  Arteriosclerosis, thrombosis, and vascular biology 20060401

• Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome.

  Metabolism: clinical and experimental 20060401

• Novel kinetic insights into treatment of unconjugated hyperbilirubinemia: phototherapy and orlistat treatment in Gunn rats.

  Pediatric research 20060401

• Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight or obese adults.

  Evidence-based nursing 20060401

• Keeping weight-loss drugs in perspective. If you're dangerously overweight, diet pills may help--but not without major lifestyle changes.

  Harvard women's health watch 20060401

• Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study.

  Arquivos brasileiros de endocrinologia e metabologia 20060401

• Pharmacological treatment of obesity.

  Arquivos brasileiros de endocrinologia e metabologia 20060401

• High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.

  Circulation research 20060303

• [Pharmacotherapy in the treatment of obesity].

  MMW Fortschritte der Medizin 20060302

• Glucose-stimulated insulin secretion correlates with beta-cell lipolysis.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20060301

• Weight loss as a treatment for nonalcoholic fatty liver disease.

  Journal of clinical gastroenterology 20060301

• Influence of weight loss on myocardial performance index.

  Heart and vessels 20060301

• Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification?

  Eating and weight disorders : EWD 20060301

• Transfer of very low density lipoprotein-associated phospholipids to activated human platelets.

  Journal of lipid research 20060201

• Development of the first potent and specific inhibitors of endocannabinoid biosynthesis.

  Biochimica et biophysica acta 20060201

• Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

  Current drug targets 20060201

• Effects of orlistat therapy on plasma concentrations of oxygenated and hydrocarbon carotenoids.

  Lipids 20060201

• [Drug treatment of obesity].

  Ugeskrift for laeger 20060109

• [Weight loss treatment of obese type 2 diabetic patients].

  Ugeskrift for laeger 20060109

• Effects of eight weeks of exercise training and orlistat therapy on body composition and maximal exercise capacity in obese females.

  Public health 20060101

• Pharmacotherapy for obesity.

  Appetite 20060101

• Pharmacologic treatment of obesity.

  Advances in psychosomatic medicine 20060101

• The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101

• Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice.

  BMC complementary and alternative medicine 20060101

• Safety of drug therapies used for weight loss and treatment of obesity.

  Drug safety 20060101

• Analysis of the XENDOS study (Xenical in the Prevention of Diabetes in Obese Subjects).

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101

• Assessment and management of the obese adult female: a clinical update for providers.

  Journal of midwifery & women's health 20060101

• Evidence of dual pathways for lipid uptake during chylomicron remnant-like particle processing by human macrophages.

  Journal of vascular research 20060101

• Pharmacological and surgical intervention for the prevention of diabetes.

  Nestle Nutrition workshop series. Clinical & performance programme 20060101

• The treatment of type 2 diabetes mellitus in youth : which therapies?

  Treatments in endocrinology 20060101

• Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.

  Asia Pacific journal of clinical nutrition 20060101

• Treatment of obesity: a challenging task.

  Contributions to nephrology 20060101

• 36 year old man presenting with pancreatitis and a history of recent commencement of Orlistat case report.

  Nutrition journal 20060101

• The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome.

  Lipids in health and disease 20060101

• Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.

  BMC psychiatry 20060101

• Orlistat: a review of its use in the management of obesity.

  Drugs 20060101

• Over-the-counter orlistat. A weight loss 'Alli' or adversary on the horizon.

  AWHONN lifelines 20060101

• Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.

  Hormones (Athens, Greece) 20060101

• [The role of fat tissue in development of metabolic disorders in patients with diabetes mellitus type 2 and obesity].

  Terapevticheskii arkhiv 20060101

• The relation of adipose tissue to cardiometabolic risk.

  Clinical cornerstone 20060101

• Role of free fatty acids in regulating gastric emptying and gallbladder contraction.

  Digestion 20060101

• Medical management of obesity.

  Acta clinica Belgica 20060101

• The effects of orlistat treatment interruption on weight and associated metabolic parameters.

  Prague medical report 20060101

• Type 2 diabetes in children: a growing epidemic.

  The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20060101

• Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa.

  The Chinese journal of physiology 20051231

• Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid.

  American journal of physiology. Endocrinology and metabolism 20051201

• Orlistat (Xenical)-induced subacute liver failure.

  European journal of gastroenterology & hepatology 20051201

• Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

  Current medical research and opinion 20051201

• Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20051201

• [Therapy of obesity-associated hypertension].

  Deutsche medizinische Wochenschrift (1946) 20051118

• Inflammatory markers and the metabolic syndrome.

  Atherosclerosis 20051101

• Pharmacologic agents for the treatment of obesity.

  Clinics in geriatric medicine 20051101

• X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

  Diabetes, obesity & metabolism 20051101

• Orlistat for the treatment of obesity: cost utility model.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20051101

• Safety of obesity drugs.

  Expert opinion on drug safety 20051101

• The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.

  Expert opinion on pharmacotherapy 20051101

• Does the English NHS have a 'Health Benefit Basket'?

  The European journal of health economics : HEPAC : health economics in prevention and care 20051101

• Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain.

  European psychiatry : the journal of the Association of European Psychiatrists 20051101

• The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.

  Current medical research and opinion 20051101

• Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004.

  Obesity research 20051101

• [Influence of orlistat therapy on serum insulin level and morphological and functional parameters of peripheral arterial circulation in obese patients].

  Vojnosanitetski pregled 20051101

• Drug therapy in prediabetes.

  Journal of the Indian Medical Association 20051101

• Use of orlistat (xenical) to treat chylous ascites.

  Journal of clinical gastroenterology 20051001

• Management of hypertension in overweight and obese patients: a practical guide for clinicians.

  Current hypertension reports 20051001

• A comparison of meal replacements and medication in weight maintenance after weight loss.

  Journal of the American College of Nutrition 20051001

• Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects.

  The American journal of the medical sciences 20051001

• Effect of orlistat in obese patients with binge eating disorder.

  Obesity research 20051001

• Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells.

  The Journal of biological chemistry 20050902

• New options for drug treatment of obesity in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20050901

• The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat.

  Digestive diseases and sciences 20050901

• Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20050901

• Childhood obesity. Treatment options.

  Best practice & research. Clinical endocrinology & metabolism 20050901

• Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).

  Journal of natural products 20050901

• The prevention of type 2 diabetes: what is the evidence?

  Minerva endocrinologica 20050901

• New drug policy in childhood obesity.

  International journal of obesity (2005) 20050901

• Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome.

  Vascular health and risk management 20050901

• The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.

  Journal of medicinal chemistry 20050811

• Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.

  International journal of obesity (2005) 20050801

• Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050801

• Exercise training as an adjunct to orlistat therapy reduces oxidative stress in obese subjects.

  The Tohoku journal of experimental medicine 20050801

• Current treatment approaches to overweight in adolescents.

  Current opinion in pediatrics 20050801

• Do the drugs that block fat absorption help with weight loss?

  Mayo Clinic women's healthsource 20050801

• Identification and structural characterization of an unusual mycobacterial monomeromycolyl-diacylglycerol.

  Molecular microbiology 20050801

• Phentermine and anaesthesia.

  Anaesthesia and intensive care 20050801

• [Medical management of primary nonalcoholic fatty liver disease].

  Medicina clinica 20050618

• Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.

  JAMA 20050615

• Pharmacotherapy for adolescent obesity: a weighty issue.

  JAMA 20050615

• Press coverage and sales of Xenical in Sweden, 1998-2000.

  European journal of clinical pharmacology 20050601

• Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages.

  Atherosclerosis 20050601

• Can type 2 diabetes mellitus be considered preventable?

  Diabetes research and clinical practice 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects.

  Acta cardiologica 20050601

• Obesity.

  Clinical evidence 20050601

• Biochemical and molecular characterization of Staphylococcus xylosus lipase.

  Biochimica et biophysica acta 20050525

• Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial.

  Biological psychiatry 20050515

• Does the pancreas really produce much more lipase than required for fat digestion?

  JOP : Journal of the pancreas 20050510

• Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland.

  International journal of obesity (2005) 20050501

• Effect of orlistat on cardiovascular disease risk in obese adults.

  Diabetes, obesity & metabolism 20050501

• Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size.

  Atherosclerosis 20050501

• A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.

  Diabetic medicine : a journal of the British Diabetic Association 20050501

• Prevention of type 2 diabetes.

  Current molecular medicine 20050501

• Meta-analysis: pharmacologic treatment of obesity.

  Annals of internal medicine 20050405

• Human triglyceride-rich lipoproteins impair glucose metabolism and insulin signalling in L6 skeletal muscle cells independently of non-esterified fatty acid levels.

  Diabetologia 20050401

• Pharmacological treatments for obesity.

  Professional nurse (London, England) 20050401

• Obesity and cardiovascular physiology: impact of some pharmacological agents.

  Current vascular pharmacology 20050401

• [Obesity pharmacological treatment].

  Revista clinica espanola 20050401

• [The role of orlistat in the treatment of obesity].

  Orvosi hetilap 20050313

• The 'expert patient': empowerment or medical dominance? The case of weight loss, pharmaceutical drugs and the Internet.

  Social science & medicine (1982) 20050301

• Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change.

  Diabetic medicine : a journal of the British Diabetic Association 20050301

• Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats.

  Hepatology (Baltimore, Md.) 20050301

• Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors?

  Experimental biology and medicine (Maywood, N.J.) 20050301

• A systematic review of drug therapy to delay or prevent type 2 diabetes.

  Diabetes care 20050301

• Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome.

  Saudi medical journal 20050301

• Pharmacological therapies for obesity.

  Gastroenterology clinics of North America 20050301

• Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.

  Methods and findings in experimental and clinical pharmacology 20050301

• Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.

  The Journal of clinical endocrinology and metabolism 20050201

• The effects of orlistat on metabolic parameters and other cardiovascular risk factors.

  Diabetes & metabolism 20050201

• [Obesity in adult patients: check up and treatment].

  Revue medicale de Bruxelles 20050201

• Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction.

  Seminars in vascular medicine 20050201

• Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20050125

• Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage.

  Diabetes/metabolism research and reviews 20050101

• Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels.

  International journal of obesity (2005) 20050101

• Pharmacologic prevention or delay of type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20050101

• Effects of different weight loss protocols on serum leptin levels in obese females.

  Physiological research 20050101

• Orlistat for obesity: benefits beyond weight loss.

  Diabetes research and clinical practice 20050101

• Reduction of body weight and co-morbidities by orlistat: The XXL--Primary Health Care Trial.

  Diabetes, obesity & metabolism 20050101

• Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.

  Diabetes, obesity & metabolism 20050101

• Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes.

  ACP journal club 20050101

• Review: orlistat and sibutramine are modestly effective for weight loss at 1 year.

  ACP journal club 20050101

• Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting.

  BMC family practice 20050101

• Preventing type 2 diabetes mellitus.

  The Journal of the American Board of Family Practice 20050101

• Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?

  Health and quality of life outcomes 20050101

• Diabesity: are weight loss medications effective?

  Treatments in endocrinology 20050101

• Spotlight on orlistat in the management of patients with obesity.

  Treatments in endocrinology 20050101

• Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes.

  BMC complementary and alternative medicine 20050101

• [Body mass loss due to orlistat therapy and multiple factors of cardiovascular risk].

  Terapevticheskii arkhiv 20050101

• [Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat].

  Therapie 20050101

• Effect of Orlistat in obese patients with heart failure: a pilot study.

  Congestive heart failure (Greenwich, Conn.) 20050101

• Does treating obesity stabilize chronic kidney disease?

  BMC nephrology 20050101

• Pharmacotherapy for obesity.

  Drugs 20050101

• [Obesity and type 2 diabetes].

  Revue medicale de Liege 20050101

• [Prevention of type 2 diabetes: a new public health challenge].

  Revue medicale de Liege 20050101

• [Efficacy and safety of a short-time orlistat treatment in obese subjects].

  Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna 20050101

• Treatment of intractable constipation with orlistat: a report of three cases.

  Pain medicine (Malden, Mass.) 20050101

• How hunger happens. The brain's role in obesity.

  Diabetes self-management 20050101

• Prevalence, predisposition and prevention of type II diabetes.

  Nutrition & metabolism 20050101

• The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach.

  PharmacoEconomics 20050101

• [Impact of the mass-reductive therapy with orlistat on 25-(OH)-D3 and PTH concentration in sera of obese, menopausal women].

  Endokrynologia Polska 20050101

• Pharmacotherapy to reduce visceral fat.

  Clinical cornerstone 20050101

• [The 'problem obesity': viewpoint of the internist].

  Annali italiani di chirurgia 20050101

• Diets, drugs, exercise, and behavioral modification: Where these work and where they do not.

  Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 20050101

• Effect of orlistat on plasma leptin levels and risk factors for the metabolic syndrome.

  Metabolic syndrome and related disorders 20050101

• Obesity: prevalence, theories, medical consequences, management, and research directions.

  Journal of the International Society of Sports Nutrition 20050101

• Addition of orlistat to conventional treatment in adolescents with severe obesity.

  European journal of pediatrics 20041201

• Modern, new pharmacotherapy for obesity. A gastrointestinal approach.

  Best practice & research. Clinical gastroenterology 20041201

• Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.

  Best practice & research. Clinical gastroenterology 20041201

• Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20041201

• Medical management of obesity in women: office-based approaches to weight management.

  Clinical obstetrics and gynecology 20041201

• The physical properties of rectal contents have effects on anorectal continence: insights from a study into the cause of fecal spotting on orlistat.

  Diseases of the colon and rectum 20041201

• Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes.

  Diabetologia 20041201

• A case series describing orlistat use in patients on psychotropic medications.

  Medicine and health, Rhode Island 20041201

• Long-term pharmacotherapy for obesity.

  Obesity research 20041201

• [Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects].

  Polskie Archiwum Medycyny Wewnetrznej 20041201

• Orlistat augments postprandial increases in glucagon-like peptide-1 in obese type 2 diabetic patients: response to Damci et al.

  Diabetes care 20041101

• G protein polymorphisms do not predict weight loss and improvement of hypertension in severely obese patients.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20041101

• [Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies].

  Psychiatrische Praxis 20041101

• What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews.

  BMJ (Clinical research ed.) 20041030

• [Pharmacotherapy of obesity].

  Ugeskrift for laeger 20041018

• [Pharmacotherapy of obesity].

  MMW Fortschritte der Medizin 20041007

• A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet.

  European journal of pharmacology 20041006

• Effectiveness of orlistat versus diet and exercise for weight gain associated with antidepressant use: a pilot study.

  Journal of clinical psychopharmacology 20041001

• Clinical pharmacotherapy for obesity: current drugs and those in advanced development.

  Current drug targets 20041001

• A perspective on the current strategies for the treatment of obesity.

  Current drug targets. CNS and neurological disorders 20041001

• Overestimation of plasma nonesterified fatty acid concentrations in heparinized blood.

  Circulation 20040928

• A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.

  Alimentary pharmacology & therapeutics 20040915

• [Screening, prevention and early therapy of type 2 diabetics].

  MMW Fortschritte der Medizin 20040902

• Effects of orlistat on obesity-related diseases - a six-month randomized trial.

  Diabetes, obesity & metabolism 20040901

• Weight gain during insulin therapy in patients with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20040901

• The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.

  Current medical research and opinion 20040901

• Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20040801

• What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions.

  Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 20040801

• Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion.

  Kidney international 20040801

• Lipid metabolic enzymes: emerging drug targets for the treatment of obesity.

  Nature reviews. Drug discovery 20040801

• Activating cancer drug discovery.

  Environmental health perspectives 20040801

• Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

  Diabetes, nutrition & metabolism 20040801

• A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2.

  The Journal of biological chemistry 20040716

• Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.

  Archives of internal medicine 20040712

• Utilization of triacylglycerol-rich lipoproteins by the working rat heart: routes of uptake and metabolic fates.

  The Journal of physiology 20040701

• [Pharmacotherapy of obesity].

  Wiener medizinische Wochenschrift (1946) 20040701

• Pharmacological and surgical treatment of obesity.

  Evidence report/technology assessment (Summary) 20040701

• Influence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal.

  Alimentary pharmacology & therapeutics 20040615

• [Treatment principles for the metabolic syndrome].

  Presse medicale (Paris, France : 1983) 20040605

• Visceral obesity without insulin resistance in late-onset obesity rats.

  Endocrinology 20040601

• Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.

  Alimentary pharmacology & therapeutics 20040601

• Rapid exchange of pancreatic lipase between triacylglycerol droplets.

  Biochimica et biophysica acta 20040601

• [Modification of conventional risk factors in coronary artery disease].

  Wiener medizinische Wochenschrift (1946) 20040601

• Obesity.

  Clinical evidence 20040601

• Smoking cessation and weight gain.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20040501

• Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.

  Diabetes care 20040501

• Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

  Health technology assessment (Winchester, England) 20040501

• Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.

  Endocrine research 20040501

• Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults.

  The American journal of cardiology 20040415

• ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes.

  Journal of lipid research 20040401

• Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.

  Metabolism: clinical and experimental 20040401

• Preventing type II diabetes mellitus.

  Journal of clinical pharmacology 20040401

• Clinical evaluation of anti-obesity drugs.

  Current drug targets 20040401

• New biologically active triterpenoid saponins from Scabiosa tschiliensis.

  Journal of natural products 20040401

• [Altering lifestyle and treating obesity, preventing type 2 diabetes?].

  Soins; la revue de reference infirmiere 20040401

• Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.

  Bangladesh Medical Research Council bulletin 20040401

• Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity.

  Cancer research 20040315

• Preventing cardiovascular events in patients with diabetes mellitus.

  The American journal of medicine 20040308

• Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity.

  Alimentary pharmacology & therapeutics 20040301

• Comment: Pharmacist intervention enhances adherence to orlistat therapy.

  The Annals of pharmacotherapy 20040301

• Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

  The Tohoku journal of experimental medicine 20040301

• Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions.

  Journal of pediatric endocrinology & metabolism : JPEM 20040301

• Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility.

  International journal of pharmaceutics 20040211

• A systematic review of the clinical effectiveness of orlistat used for the management of obesity.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20040201

• The pathophysiology of faecal spotting in obese subjects during treatment with orlistat.

  Alimentary pharmacology & therapeutics 20040201

• [Struggle about the best reducing diet, Fat gone by means of more fat?].

  MMW Fortschritte der Medizin 20040115

• Inhibition of lipase activity and lipolysis in rat islets reduces insulin secretion.

  Diabetes 20040101

• Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes.

  Diabetes care 20040101

• XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

  Diabetes care 20040101

• What role for weight-loss medication? Weighing the pros and cons for obese patients.

  Postgraduate medicine 20040101

• Effects of short-period exercise training and orlistat therapy on body composition and maximal power production capacity in obese patients.

  Physiological research 20040101

• Non-oxidative metabolism of ethanol by rat pancreatic acini.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20040101

• The management of hypertension in the overweight and obese patient: is weight reduction sufficient?

  Drugs 20040101

• Obesity: an overview on its current perspectives and treatment options.

  Nutrition journal 20040101

• [Complex assessment of metabolic parameters in obese patients treated with xenical].

  Terapevticheskii arkhiv 20040101

• Metabolic and cardiovascular improvements after biliopancreatic diversion in a severely obese patient.

  Cardiovascular diabetology 20040101

• The management of hypertension in the overweight and obese patient: is weight reduction sufficient?

  Drugs 20040101

• The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds.

  Tuberculosis (Edinburgh, Scotland) 20040101

• [Impaired fat tolerance as a risk factor of insulin resistance in young patients with obesity].

  Klinicheskaia meditsina 20040101

• [Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia].

  Przeglad lekarski 20040101

• Long-term pharmacotherapy for obesity and overweight.

  The Cochrane database of systematic reviews 20040101

• Pouch dilatation following laparoscopic adjustable gastric banding: psychobehavioral factors (can psychiatrists predict pouch dilatation?).

  Obesity surgery 20040101

• Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20040101

• Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20040101

• [Pharmacological treatment of obesity].

  Revista de medicina de la Universidad de Navarra 20040101

• Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101

• Pharmacotherapy of obesity.

  Clinics in dermatology 20040101

• Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

  Drugs 20040101

• Orlistat: a review of its use in the management of patients with obesity.

  Drugs 20040101

• [Pharmacological treatment for obesity].

  Gaceta medica de Mexico 20040101

• Advances in diabetes for the millennium: nutritional therapy of type 2 diabetes.

  MedGenMed : Medscape general medicine 20040101

• [Methodology and quality control in EPIGRAM, a pharmacoepidemiological study of obesity in general practice].

  Therapie 20040101

• Managing type 2 diabetes mellitus in patients with obesity.

  Treatments in endocrinology 20040101

• [A randomized comparison of a course in gourmet cookery versus behavior modification in the treatment of severe obesity].

  Ugeskrift for laeger 20031215

• Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force.

  Annals of internal medicine 20031202

• Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20031201

• Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20031201

• Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20031201

• Screening for pancreatic exocrine insufficiency in patients with diabetes mellitus.

  The American journal of gastroenterology 20031201

• Obesity and pharmacologic therapy.

  Endocrinology and metabolism clinics of North America 20031201

• Fat pill for teens. Xenical may have the FDA's blessing, but is it a good idea?

  Time 20031201

• Obesity.

  Clinical evidence 20031201

• [Effectiveness of therapeutic interventions in obesity].

  Praxis 20031119

• Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain.

  The Journal of cell biology 20031110

• Pharmacist intervention enhances adherence to orlistat therapy.

  The Annals of pharmacotherapy 20031101

• Success rate of Orlistat in primary-care practice is limited by failure to follow prescribing recommendations: the referral letter content vs clinical reality.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20031101

• Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.

  Journal of hypertension 20031101

• Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects.

  The British journal of nutrition 20031101

• 2: Recent advances in therapy of diabetes.

  The Medical journal of Australia 20031020

• [New therapeutic options in obesity].

  MMW Fortschritte der Medizin 20031016

• The implementation of nutritional advice for people with diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20031001

• The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents.

  Journal of the American College of Nutrition 20031001

• Natural abundance 13C-NMR spectroscopy for the quantitative determination of fecal fat.

  Clinical biochemistry 20031001

• Effect of orlistat on fat absorption in rats: a comparison of normal rats and rats with diverted bile and pancreatic juice.

  Lipids 20031001

• [Is type-2 diabetes mellitus preventable?].

  Orvosi hetilap 20030928

• Management of the overweight patient with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20030901

• The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.

  Romanian journal of gastroenterology 20030901

• Orlistat reduces features of the metabolic syndrome: the XENDOS study.

  Diabetes, obesity & metabolism 20030901

• Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats.

  The Journal of pediatrics 20030901

• [Long-term drug therapy of obesity in 2002--pharmacoeconomic aspects].

  Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti 20030901

• Importance of lipolysis in oral cavity for orosensory detection of fat.

  American journal of physiology. Regulatory, integrative and comparative physiology 20030801

• VLDL induces adipocyte differentiation in ApoE-dependent manner.

  Arteriosclerosis, thrombosis, and vascular biology 20030801

• Case study: metformin-associated lactic acidosis: could orlistat be relevant?

  Diabetes care 20030801

• Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20030801

• [What effect does losing weight have on hypertension?].

  MMW Fortschritte der Medizin 20030710

• Obesity and hyperhomocysteinaemia after kidney transplantation.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030701

• Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes.

  Diabetes care 20030601

• Pharmacological therapy of obesity: past, present, and future.

  The Journal of clinical endocrinology and metabolism 20030601

• Drug strategies for the treatment of obesity.

  IDrugs : the investigational drugs journal 20030601

• Orlistat treatment in obese prepubertal children: a pilot study.

  Acta paediatrica (Oslo, Norway : 1992) 20030601

• [French diabetologists' standpoint on the prevention of type 2 diabetes. A survey carried out during the ALFEDIAM Convention Bordeaux 2003].

  Diabetes & metabolism 20030601

• [Is it possible to prevent type 2 diabetes?].

  Annales d'endocrinologie 20030601

• Improvement in hypertrophic cardiomyopathy after significant weight loss: case report.

  Southern medical journal 20030601

• Orlistat in the treatment of obesity.

  Primary care 20030601

• The management of the obese diabetic patient.

  Primary care 20030601

• Diet associated with regular physical activity or drugs. A longitudinal study on obesity management.

  Minerva gastroenterologica e dietologica 20030601

• [A drug help in reducing? Risk profile decides whether and how].

  MMW Fortschritte der Medizin 20030522

• National trends in antiobesity medication use.

  Archives of internal medicine 20030512

• Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI.

  Journal of lipid research 20030501

• Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

  Diabetes, obesity & metabolism 20030501

• Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors.

  Diabetes, obesity & metabolism 20030501

• Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans.

  American journal of physiology. Gastrointestinal and liver physiology 20030501

• Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20030501

• Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia.

  The American journal of cardiology 20030415

• Experimental drugs take aim at obesity.

  JAMA 20030409

• Orlistat enhances warfarin effect.

  The Annals of pharmacotherapy 20030401

• Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat.

  Alimentary pharmacology & therapeutics 20030401

• Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers.

  Journal of clinical pharmacology 20030401

• Orlistat in the treatment of NASH: a case series.

  The American journal of gastroenterology 20030401

• Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.

  Clinical therapeutics 20030401

• [Prevention of type 2 diabetes: lifestyle changes or pharmacological interventions?].

  Revue medicale de Liege 20030401

• [Fat-normalizing nutrition. Therewith your patients escape from the yo-yo effect].

  MMW Fortschritte der Medizin 20030327

• [Overweight patient has tried many times to lose weight. What helps against stubborn fat padding?].

  MMW Fortschritte der Medizin 20030306

• [Weight loss via drug therapy].

  Der Internist 20030301

• Management of weight gain associated with antipsychotics.

  Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20030301

• VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass.

  Biochimica et biophysica acta 20030220

• Obesity drug pipeline not so fat.

  Science (New York, N.Y.) 20030207

• Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA.

  American journal of physiology. Endocrinology and metabolism 20030201

• Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20030201

• Treatment of obesity: an update on anti-obesity medications.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20030201

• Medical management of obesity: a clinical imperative?

  Current diabetes reports 20030201

• Prevention of type 2 diabetes: are we ready?

  Minerva medica 20030201

• Glucagon-like peptide 1 and fatty acids amplify pulsatile insulin secretion from perifused rat islets.

  The Biochemical journal 20030101

• Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20030101

• Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.

  Drugs 20030101

• Obesity.

  Clinical medicine (London, England) 20030101

• Weight management and current options in pharmacotherapy: orlistat and sibutramine.

  Clinical therapeutics 20030101

• Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

  PharmacoEconomics 20030101

• Medical management of obesity: present and future therapy.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20030101

• Current management strategies for coexisting diabetes mellitus and obesity.

  Drugs 20030101

• Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR).

  Cardiovascular diabetology 20030101

• Pharmacotherapy of obesity: an update.

  Nutrition in clinical care : an official publication of Tufts University 20030101

• The treatment of obesity.

  Missouri medicine 20030101

• Psychotropic drug-induced weight gain alleviated with orlistat: a case series.

  Psychopharmacology bulletin 20030101

• Long-term pharmacotherapy for obesity and overweight.

  The Cochrane database of systematic reviews 20030101

• The prevention of type 2 diabetes mellitus.

  Clinical medicine (London, England) 20030101

• The acute effect of orlistat on endothelial function in young obese women.

  International journal of clinical pharmacology research 20030101

• Pathogenesis and management of diabetic dyslipidemia.

  Treatments in endocrinology 20030101

• Pharmacotherapy of obesity.

  Best practice & research. Clinical endocrinology & metabolism 20021201

• Pharmacological management of obesity.

  Expert opinion on pharmacotherapy 20021201

• Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.

  Obesity research 20021201

• New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.

  Diabetes & metabolism 20021201

• The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.

  Archives of internal medicine 20021125

• Endothelial cell-derived lipase mediates uptake and binding of high-density lipoprotein (HDL) particles and the selective uptake of HDL-associated cholesterol esters independent of its enzymic activity.

  The Biochemical journal 20021115

• Administration of orlistat in a patient with familial hyperchylomicronemia.

  Atherosclerosis 20021101

• The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.

  Diabetes, obesity & metabolism 20021101

• Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension.

  Journal of hypertension 20021101

• Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus.

  Diabetic medicine : a journal of the British Diabetic Association 20021101

• The new role of pharmacotherapy for weight reduction in obesity.

  International journal of clinical practice 20021101

• New pharmacological tools for obesity.

  Journal of endocrinological investigation 20021101

• Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.

  Pharmacopsychiatry 20021101

• Orlistat-induced cutaneous leukocytoclastic vasculitis.

  Arthritis and rheumatism 20021015

• Transfer of orlistat through oil-water interfaces.

  Chemistry and physics of lipids 20021001

• Response to Lamotte et Al. 'A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.'.

  Diabetes care 20021001

• Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior.

  Journal of clinical psychopharmacology 20021001

• Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine.

  Clinical nutrition (Edinburgh, Scotland) 20021001

• Obesity.

  American family physician 20021001

• Major depressive episodes and diet pills.

  Expert opinion on pharmacotherapy 20021001

• [Obesity in patients with diabetes].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat?

  Medicine, science, and the law 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• Antiobesity drugs: current and future issues.

  Current diabetes reports 20021001

• Recent developments in the treatment of obesity-related hypertension.

  Current opinion in nephrology and hypertension 20020901

• Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension.

  Journal of hypertension 20020901

• Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects.

  Journal of clinical pharmacology 20020901

• Adolescent obesity: identifying a new group of at-risk youth.

  Pediatric annals 20020901

• Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study.

  International journal of clinical practice 20020901

• [Primary prevention of diabetes mellitus by pharmacological intervention].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study].

  Revue medicale de Liege 20020901

• [A case of acute cholestatic hepatitis associated with Orlistat].

  Taehan Kan Hakhoe chi = The Korean journal of hepatology 20020901

• Effects of lipoprotein lipase on uptake and transcytosis of low density lipoprotein (LDL) and LDL-associated alpha-tocopherol in a porcine in vitro blood-brain barrier model.

  The Journal of biological chemistry 20020809

• Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese.

  Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 20020801

• Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

  Diabetes care 20020701

• Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions.

  Obesity research 20020701

• Effects of orlistat on fat-soluble vitamins in obese adolescents.

  Pharmacotherapy 20020701

• Options for pharmacological management of obesity in patients treated with atypical antipsychotics.

  International clinical psychopharmacology 20020701

• Medical management of obesity.

  Seminars in gastrointestinal disease 20020701

• Demand, appropriateness and prescribing of 'lifestyle drugs': a consultation survey in general practice.

  Family practice 20020601

• Additive gastrointestinal effects with concomitant use of olestra and orlistat.

  The Annals of pharmacotherapy 20020601

• Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

  Diabetes care 20020601

• Combining behavioral and pharmacological treatments for obesity.

  Obesity research 20020601

• Orlistat in the treatment of Type 2 diabetes mellitus.

  Expert opinion on pharmacotherapy 20020501

• Virolytic action of lipoprotein lipase on hepatitis C virus in human sera.

  Medical microbiology and immunology 20020501

• Orlistat: its current status as an anti-obesity drug.

  European journal of pharmacology 20020412

• Biosynthetic precursors of the lipase inhibitor lipstatin.

  The Journal of organic chemistry 20020405

• The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity.

  The Journal of clinical endocrinology and metabolism 20020401

• Results of obesity treatment.

  Annales d'endocrinologie 20020401

• Roche turns to DM to boost patient compliance with its weight loss drug.

  Disease management advisor 20020401

• [Orlistat. A treatment of limited value for obese persons].

  Revue de l'infirmiere 20020401

• [Anti-obesity drugs: sibutramine and orlistat].

  Medicina clinica 20020330

• Serine and threonine beta-lactones: a new class of hepatitis A virus 3C cysteine proteinase inhibitors.

  The Journal of organic chemistry 20020308

• Orlistat misuse in bulimia nervosa.

  The American journal of psychiatry 20020301

• Can drugs help you lose weight?

  Harvard heart letter : from Harvard Medical School 20020301

• [Management of overweight and obese patient. New acquisition].

  Minerva gastroenterologica e dietologica 20020301

• Obesity pharmacology: past, present, and future.

  Current opinion in gastroenterology 20020301

• The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy.

  Journal of clinical psychopharmacology 20020201

• A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.

  Diabetes care 20020201

• Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band.

  Obesity surgery 20020201

• Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients.

  Transplantation proceedings 20020201

• Orlistat: a second look. At best, a minor adjunct to dietary measures.

  Prescrire international 20020201

• [Treatment in the community health centers in accordance with recommendations of the Medical Products Agency. Unsatisfactory weight reduction with orlistat].

  Lakartidningen 20020131

• Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.

  The American journal of cardiology 20020115

• Obesity.

  The Western journal of medicine 20020101

• Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.

  Diabetes, obesity & metabolism 20020101

• [Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia].

  Terapevticheskii arkhiv 20020101

• Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects.

  Diabetes, obesity & metabolism 20020101

• Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• Are soft tissue composition of bone and non-bone pixels in spinal bone mineral measurements by DXA similar? Impact of weight loss.

  Clinical physiology and functional imaging 20020101

• [Are drugs necessary in the treatment of obesity?].

  Medicinski pregled 20020101

• [Weight reduction. Antiobesity drug treatment in type-2 diabetics].

  Pharmazie in unserer Zeit 20020101

• Constipation, polyuria, polydipsia, and edema associated with orlistat.

  The Annals of pharmacotherapy 20020101

• Orlistat use in type 2 diabetes.

  The Annals of pharmacotherapy 20020101

• Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• Pharmacologic agents for weight reduction.

  The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia 20020101

• Utilisation of fatty acid and triacylglycerol by rat macrophages: the effect of endotoxin.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20020101

• Obesity, cardiovascular risk and pharmacotherapy.

  Blood pressure 20020101

• [Efficacy of orlistat in the treatment of constitutional-alimentary obesity in patients with high risk of cardiovascular complications].

  Kardiologiia 20020101

• Orlistat use in overweight women with mild hypercholesterolemia.

  International journal of clinical pharmacology research 20020101

• [Pharmacological treatment of obesity].

  Anales del sistema sanitario de Navarra 20020101

• Pharmacotherapy of obesity: currently marketed and upcoming agents.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Case report of abuse of Orlistat.

  Eating behaviors 20020101

• Management of obesity in the elderly: special considerations.

  Treatments in endocrinology 20020101

• [Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment].

  Orvosi hetilap 20011216

• ['Xenical doesn't function'--theory and reality].

  Lakartidningen 20011212

• American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.

  Medicine and science in sports and exercise 20011201

• Bulimia nervosa and misuse of orlistat: two case reports.

  The International journal of eating disorders 20011201

• Primary care diabetes. What options are there?

  Australian family physician 20011201

• [Obesity and diabetes mellitus].

  Minerva gastroenterologica e dietologica 20011201

• [Application for exemption concerning Xenical was refused without explanation].

  Lakartidningen 20011107

• [Drugs for obesity. Why are obese patients diferent?].

  Medicina clinica 20011103

• Role of nonesterified fatty acids in necrotizing pancreatitis: an in vivo experimental study in rats.

  Pancreas 20011101

• Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI.

  Journal of lipid research 20011101

• Interaction between orlistat and antihypertensive drugs.

  The Annals of pharmacotherapy 20011101

• [Inhibitors of absorption as anti-obesity drugs].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20011101

• The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20011101

• Current methods used for defining, measuring, and treating obesity.

  Seminars in urologic oncology 20011101

• [Therapy of obesity. Setting realistic goals].

  MMW Fortschritte der Medizin 20011018

• [Hypertension and cardiomyopathy in obesity. Treat the heart simultaneously].

  MMW Fortschritte der Medizin 20011018

• Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience.

  Controlled clinical trials 20011001

• Orlistat inhibits dietary cholesterol absorption.

  Obesity research 20011001

• Drug treatment of obesity.

  Reviews in endocrine & metabolic disorders 20011001

• Pathophysiology and treatment of the dyslipidemia of insulin resistance.

  Current cardiology reports 20010901

• Weighing the options in the pharmacotherapy of obesity.

  International journal of clinical pharmacology and therapeutics 20010901

• Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.

  British journal of pharmacology 20010901

• About orlistat.

  Eating and weight disorders : EWD 20010901

• Obesity: a new paradigm in endocrinology.

  Eating and weight disorders : EWD 20010901

• The advances on the knowledge base of obesity and future therapeutic directions.

  Eating and weight disorders : EWD 20010901

• [Obesity and cardiovascular risk].

  Annales d'endocrinologie 20010901

• Influence of orlistat on bone turnover and body composition.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20010801

• Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety.

  Archives of internal medicine 20010801

• Evidence for specific ceramidase present in the intestinal contents of rats and humans.

  Lipids 20010801

• Pharmacologic options for the treatment of obesity.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010715

• Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.

  American journal of physiology. Gastrointestinal and liver physiology 20010701

• Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid).

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20010701

• Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. A cohort study.

  European journal of clinical pharmacology 20010701

• [Wellbeing or happiness medications?].

  Atencion primaria 20010630

• Comparative evaluation of fecal fat excretion induced by orlistat and chitosan.

  Obesity research 20010601

• Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.

  The American journal of gastroenterology 20010601

• Treating obesity in the family practice setting.

  Postgraduate medicine 20010601

• Exploring synergies in the treatment of obesity.

  Postgraduate medicine 20010601

• Emerging strategies for weight management. Summary.

  Postgraduate medicine 20010601

• Lifestyle drugs: issues for debate.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010515

• Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact.

  Clinical chemistry 20010501

• Surface behaviour of bile salts and tetrahydrolipstatin at air/water and oil/water interfaces.

  Chemistry and physics of lipids 20010501

• Current pharmacological approaches to the treatment of obesity.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20010501

• [Hepatotoxicity of medications].

  Presse medicale (Paris, France : 1983) 20010414

• Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans.

  Gastroenterology 20010401

• Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

  The American journal of cardiology 20010401

• The role of orlistat in weight management.

  Australian family physician 20010401

• Obesity and free fatty acids: double trouble.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20010401

• Obesity drug endorsed by NICE.

  BMJ (Clinical research ed.) 20010317

• Use of the tape stripping technique for directly quantifying esterase activities in human stratum corneum.

  Analytical biochemistry 20010301

• Orlistat--a novel weight loss therapy.

  The Annals of pharmacotherapy 20010301

• Toward optimal health: the experts discuss weight control drugs. Interview by Jodi Godfrey Meisler.

  Journal of women's health & gender-based medicine 20010301

• Diabetic ketoacidosis associated with orlistat treatment.

  Diabetes care 20010301

• Kinetic evolution of unmixing in an AlLi alloy using x-ray intensity fluctuation spectroscopy.

  Physical review. E, Statistical, nonlinear, and soft matter physics 20010301

• Current pharmacotherapy for weight loss: a review and implications for plastic surgeons.

  Aesthetic surgery journal 20010301

• Weight change and blood coagulability and fibrinolysis in healthy obese women.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20010201

• Orlistat associated with hypertension. Roche concludes that there is not evidence of a casual association.

  BMJ (Clinical research ed.) 20010113

• Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt.

  BMJ (Clinical research ed.) 20010113

• Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic beta-cells (HIT).

  Diabetes 20010101

• Orlistat associated subacute hepatic failure.

  Journal of hepatology 20010101

• [Ten questions on the treatment of obesity: from dieting to surgery].

  Revue medicale de la Suisse romande 20010101

• Plasma lipases and lipid transfer proteins increase phospholipid but not free cholesterol transfer from lipid emulsion to high density lipoproteins.

  BMC biochemistry 20010101

• Anti-obesity drugs: a critical review of current therapies and future opportunities.

  Pharmacology & therapeutics 20010101

• A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.

  Health technology assessment (Winchester, England) 20010101

• Pharmacological treatment of obesity in paediatric patients.

  Paediatric drugs 20010101

• Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101

• Treating obesity: a new target for prevention of coronary heart disease.

  Progress in cardiovascular nursing 20010101

• Online prescriptions of pharmaceuticals: where is the evidence for harm or for benefit? A call for papers--and for reflection.

  Journal of medical Internet research 20010101

• Orlistat: in the prevention and treatment of type 2 diabetes mellitus.

  Drugs 20010101

• [Obesity: therapeutic aspects].

  Bulletin et memoires de l'Academie royale de medecine de Belgique 20010101

• [Obesity: principles of drug therapy].

  Therapeutische Umschau. Revue therapeutique 20000801

• Depression induced by orlistat (Xenical).

  Canadian journal of psychiatry. Revue canadienne de psychiatrie 20000201

• Orlistat.

  Heart disease (Hagerstown, Md.) 20000101

• Orlistat: a review of its use in the management of obesity.

  Drugs 19991001

• New aspects in the management of obesity: operation and the impact of lipase inhibitors.

  Current opinion in lipidology 19990201